Patent Grant
11413145
The present invention generally provides improved medical devices, systems, and methods, typically for treatment of heart valve disease and/or for altering characteristics of one or more valves of the body. Exemplary embodiments of the invention include implants for treatment of mitral valve regurgitation.
The human heart receives blood from the organs and tissues via the veins, pumps that blood through the lungs where the it becomes enriched with oxygen, and propels the oxygenated blood out of the heart to the arteries so that the organ systems of the body can extract the oxygen for proper function. Deoxygenated blood flows back to the heart where it is once again pumped to the lungs.
As can generally be seen in
The heart has four valves generally configured to selectively transmit blood flow in the correct direction during the cardiac cycle. The valves that separate the atria from the ventricles are referred to as the atrioventricular (or AV) valves. The AV valve between the left atrium and the left ventricle is the mitral valve. The AV valve between the right atrium and the right ventricle is the tricuspid valve. The pulmonary valve directs blood flow to the pulmonary artery and thence to the lungs; blood returns to the left atrium via the pulmonary veins. The aortic valve directs flow through the aorta and thence to the periphery. There are normally no direct connections between the ventricles or between the atria.
The mechanical heartbeat is triggered by an electrical impulse which spreads throughout the cardiac tissue. Opening and closing of heart valves may occur primarily as a result of pressure differences between chambers, those pressures resulting from either passive filling or chamber contraction. For example, the opening and closing of the mitral valve may occur as a result of the pressure differences between the left atrium and the left ventricle.
At the beginning of ventricular filling (diastole) the aortic and pulmonary valves are closed to prevent back flow from the arteries into the ventricles. Shortly thereafter, the AV valves open to allow unimpeded flow from the atria into the corresponding ventricles. Shortly after ventricular systole (i.e., ventricular emptying) begins, the tricuspid and mitral valves normally shut, forming a seal which prevents flow from the ventricles back into the corresponding atria.
Unfortunately, the AV valves may become damaged or may otherwise fail to function properly, resulting in improper closing. The AV valves are complex structures that generally include an annulus, leaflets, chordae and a support structure. Each atrium interfaces with its valve via an atrial vestibule. The mitral valve has two leaflets; the analogous structure of the tricuspid valve has three leaflets, and apposition or engagement of corresponding surfaces of leaflets against each other helps provide closure or sealing of the valve to prevent blood flowing in the wrong direction. Failure of the leaflets to seal during ventricular systole is known as malcoaptation, and may allow blood to flow backward through the valve (regurgitation). Heart valve regurgitation can have serious consequences to a patient, often resulting in cardiac failure, decreased blood flow, lower blood pressure, and/or a diminished flow of oxygen to the tissues of the body. Mitral regurgitation can also cause blood to flow back from the left atrium to the pulmonary veins, causing congestion. Severe valvular regurgitation, if untreated, can result in permanent disability or death.
A variety of therapies have been applied for treatment of mitral valve regurgitation, and still other therapies may have been proposed but not yet actually used to treat patients. While several of the known therapies have been found to provide benefits for at least some patients, still further options would be desirable. For example, pharmacologic agents (such as diuretics and vasodilators) can be used with patients having mild mitral valve regurgitation to help reduce the amount of blood flowing back into the left atrium. However, medications can suffer from lack of patient compliance. A significant number of patients may occasionally (or even regularly) fail to take medications, despite the potential seriousness of chronic and/or progressively deteriorating mitral valve regurgitation. Pharmacological therapies of mitral valve regurgitation may also be inconvenient, are often ineffective (especially as the condition worsens), and can be associated with significant side effects (such as low blood pressure).
A variety of surgical options have also been proposed and/or employed for treatment of mitral valve regurgitation. For example, open-heart surgery can replace or repair a dysfunctional mitral valve. In annuloplasty ring repair, the posterior mitral annulus can be reduced in size along its circumference, optionally using sutures passed through a mechanical surgical annuloplasty sewing ring to provide coaptation. Open surgery might also seek to reshape the leaflets and/or otherwise modify the support structure. Regardless, open mitral valve surgery is generally a very invasive treatment carried out with the patient under general anesthesia while on a heart-lung machine and with the chest cut open. Complications can be common, and in light of the morbidity (and potentially mortality) of open-heart surgery, the timing becomes a challenge-sicker patients may be in greater need of the surgery, but less able to withstand the surgery. Successful open mitral valve surgical outcomes can also be quite dependent on surgical skill and experience.
Given the morbidity and mortality of open-heart surgery, innovators have sought less invasive surgical therapies. Procedures that are done with robots or through endoscopes are often still quite invasive, and can also be time consuming, expensive, and in at least some cases, quite dependent on the surgeon's skill. Imposing even less trauma on these sometimes frail patients would be desirable, as would be providing therapies that could be successfully implemented by a significant number of physicians using widely distributed skills. Toward that end, a number of purportedly less invasive technologies and approaches have been proposed. These include devices which seek to re-shape the mitral annulus from within the coronary sinus; devices that attempt to reshape the annulus by cinching either above to below the native annulus; devices to fuse the leaflets (imitating the Alfieri stitch); devices to re-shape the left ventricle, and the like. Perhaps most widely known, a variety of mitral valve replacement implants have been developed, with these implants generally replacing (or displacing) the native leaflets and relying on surgically implanted structures to control the blood flow paths between the chambers of the heart. While these various approaches and tools have met with differing levels of acceptance, none has yet gained widespread recognition as an ideal therapy for most or all patients suffering from mitral valve regurgitation.
Because of the challenges and disadvantages of known minimally invasive mitral valve regurgitation therapies and implants, still further alternative treatments have been proposed. Some of the alternative proposals have called for an implanted structure to remain within the valve annulus throughout the heart beat cycle. One group of these proposals includes a cylindrical balloon or the like to remain implanted on a tether or rigid rod extending between the atrium and the ventricle through the valve opening. Another group relies on an arcuate ring structure or the like, often in combination with a buttress or structural cross-member extending across the valve so as to anchor the implant. Unfortunately, sealing between the native leaflets and the full perimeter of a balloon or other coaxial body may prove challenging, while the significant contraction around the native valve annulus during each heart beat may result in significant fatigue failure issues during long-term implantation if a buttress or anchor interconnecting cross member is allowed to flex. Moreover, the significant movement of the tissues of the valve may make accurate positioning of the implant challenging regardless of whether the implant is rigid or flexible.
In light of the above, it would be desirable to provide improved medical devices, systems, and methods. It would be particularly desirable to provide new techniques for treatment of mitral valve regurgitation and other heart valve diseases, and/or for altering characteristics of one or more of the other valves of the body. The need remains for a device which can directly enhance leaflet coaptation (rather than indirectly via annular or ventricular re-shaping) and which does not disrupt leaflet anatomy via fusion or otherwise, but which can be deployed simply and reliably, and without excessive cost or surgical time. It would be particularly beneficial if these new techniques could be implemented using a less-invasive approach, without stopping the heart or relying on a heart-lung machine for deployment, and without relying on exceptional skills of the surgeon to provide improved valve and/or heart function.
The present invention generally provides improved medical devices, systems, and methods. In exemplary embodiments, the invention provides new implants, implant systems, and methods for treatment of mitral valve regurgitation and other valve diseases. The implants will generally include a coaptation assist body which remains within the blood flow path as the leaflets of the valve move back and forth between an open-valve configuration and a closed valve configuration. The exemplary coaptation assist bodies or valve bodies may be relatively thin, elongate (along the blood flow path), and/or conformable structures which extend laterally across some, most, or all of the width of the valve opening, allowing the native leaflets to engage and seal against the opposed surfaces on either side of the valve body. To allow safe and effective, long-term operation of the valve tissue, the valve body may be laterally offset from the centroid of the overall valve, and/or may curve laterally across the valve opening so as to mimic the natural, pre-treatment geometry of the coaptation zone directly between the two native mitral valve leaflets. The presence of the valve body between the native leaflets can enhance sealing by filling gaps between the mal-coapting leaflet surfaces, and/or the implanted valve body can allow the leaflets to coapt with axially offset regions of the opposed coaptation surfaces of the valve body.
Though the valve body will generally remain within the blood flow path of the valve (typically with blood passing on either side of the valve body during diastole), the valve body may move and/or deform significantly to help maintain natural movement of the heart tissues. As the valve opens during diastole, the valve body may move somewhat with the flow, somewhat like a middle leaflet or sail around which the blood passes, as well as with movement of the heart tissues to which the valve body is mounted. As the valve moves from the open configuration toward the closed configuration, the movement of the native valve leaflet tissue, valve-body support tissues (to which the valve body is anchored), and blood within the heart may help to move the valve body back into a desirable configuration for sealing. Surprisingly, separate deployment of independent anchors near each of the two commissures may greatly facilitate and expedite accurate positioning and support of the valve body, with an exemplary triangular valve body employing a third anchor between the papillary muscles (or otherwise within the ventricle). The exemplary valve body includes an outer surface comprising ePTFE or other biocompatible and non-thrombogenic materials, ideally formed as a layer over a fluid absorbing foam or other matrix that swells toward a desired nominal three-dimensional valve body shape after introduction into the heart, with the valve body shape optionally being selected after one or more of the anchors has been deployed. Advantageously, the implants described herein can be placed into a patient's beating heart and accurately positioned in alignment with the mitral valve without open heart surgery, typically via a patient's vasculature and/or using minimally invasive surgical techniques, and often using a catheter deployment system having a desirably small profile. Hence, the invention can provide simple, cost-effective, and less invasive devices, systems, and methods for treating a range of dysfunction of a heart valve, e.g., in the treatment of organic and functional mitral valve regurgitation.
In a first aspect, the invention provides a method for treating mal-coaptation of a heart valve in a patient. The heart valve has an annulus and first and second leaflets. The annulus defines a valve axis extending along a blood flow path, and the first and second leaflets have a coaptation zone defining a curve extending across the flow path. The method comprises introducing an implant into the heart while the implant is in a first configuration. The implant is deployed from the first configuration to a second configuration within the heart. The implant in the second configuration has a coaptation assist body with first and second opposed coaptation surfaces. The deployed implant is supported so that the coaptation assist body is offset from the axis of the heart valve along the coaptation zone. The first leaflet of the heart valve seals or coapts with the first coaptation surface and the second leaflet of the heart valve seals or coapts with the second coaptation surface such that the mal-coaptation of the heart valve is mitigated.
In another aspect, the invention provides a method for treating mal-coaptation of a heart valve in a patient. The heart valve has first and second leaflets with a first commissure at a first junction of the first and second leaflets and a second commissure at a second junction of the first and second leaflets. The method comprises selectively deploying a first anchor at a first target location near the first commissure. A second anchor is selectively deployed at a second target location near the second commissure. A coaptation assist body is introduced into the heart, the coaptation assist body having first and second opposed coaptation surfaces. The coaptation assist body is supported with the first anchor so that a first lateral edge of the coaptation assist body extends toward the first commissure, and the coaptation assist body is supported with the second anchor so that a second lateral edge of the coaptation assist body extends toward the second commissure. The first leaflet of the heart valve coapts with the first coaptation surface and the second leaflet of the heart valve coapts with the second coaptation surface such that the mal-coaptation of the heart valve is mitigated
In an apparatus aspect, the invention provides an implant for treating mal-coaptation of a heart valve in a patient. The heart valve has an annulus and first and second leaflets with a first commissure at a first junction of the first and second leaflets and a second commissure at a second junction of the first and second leaflets. The implant comprises a coaptation assist body having an axis and first and second opposed major coaptation surfaces. Each coaptation surface extends laterally between a first lateral edge and a second lateral edge of the coaptation assist body. A first anchor is selectively deployable at a first target location of the heart near the first commissure and coupleable to the coaptation assist body so that the first lateral edge is oriented toward the first commissure. A second anchor is selectively deployable, independently of the deployment of the first anchor, at a second target location of the heart near the second commissure, and is coupleable with the coaptation assist device so that the second lateral edge is oriented toward the second commissure, such that the first leaflet of the heart valve coapts with the first coaptation surface and the second leaflet of the heart valve coapts with the second coaptation surface sufficiently that the mal-coaptation of the heart valve is mitigated
In another device aspect the invention provides a coaptation assist implant for treating mal-coaptation of a heart valve in a patient. The heart valve has an annulus and first and second leaflets, the annulus defining a valve axis extending along a blood flow path. The first and second leaflets have a coaptation zone defining a curve extending across the flow path. The implant comprises a coaptation assist body having an axis and first and second opposed major coaptation surfaces. Each coaptation surface extends laterally between a first lateral edge and a second lateral edge of the coaptation assist body. The coaptation assist body is supportable within the heart so that the axis of the implant extends along the axis of the valve with the first and second lateral sides of the coaptation assist body extend along the curve of the coaptation zone of the heart valve. The coaptation assist body of the supported implant is sufficiently laterally conformable that engagement between the implant and the heart laterally bends the coaptation assist body between the edges toward the curve defined by the coaptation zone of the heart valve
In yet another device aspect, the invention provides a coaptation assist implant for treating mal-coaptation of a heart valve in a patient. The heart valve has an annulus and first and second leaflets, the annulus defining a valve axis extending along a blood flow path. The first and second leaflets have a coaptation zone defining a curve extending across the flow path. The implant comprises a coaptation assist body having an axis and first and second opposed major coaptation surfaces. Each coaptation surface extends laterally between a first lateral edge and a second lateral edge of the coaptation assist body. The coaptation assist body is introducible into the heart and supportable within the heart so that the axis of the coaptation assist body extends along the axis of the valve with the first and second lateral sides of the coaptation assist body extending, fully or partially, along the curve of the coaptation zone of the heart valve. The coaptation assist body is deployable from a first configuration to a second configuration by removing the coaptation assist body from within a surrounding deployment catheter.
In a system aspect, the invention provides a coaptation assist system for treating malcoaptation of a heart valve in a patient. The heart valve has an annulus and first and second leaflets. The annulus defines a valve axis extending along a blood flow path. The system comprises a deployment catheter system including a catheter body having a proximal end and a distal end. The distal end is steerable within the heart from the proximal end. A first anchor is selectively deployable from the distal end of the catheter body at a first target location of the heart near the first commissure. A coaptation assist body has an axis and first and second opposed major coaptation surfaces. Each coaptation surface extends laterally between a first lateral edge and a second lateral edge of the coaptation assist body. The coaptation assist body is introducible into the heart and coupleable in vivo with the first anchor after the first anchor is deployed in the heart so that the first lateral edge extends toward the first commissure.
In exemplary embodiments, a second anchor may be selectively deployable at a second target location, and a distal ventricular anchor may be selectively deployable at a third target locations, the selection of the target locations ideally being substantially independent of each other. Optionally, in vivo coupling of the coaptation assist body to the second anchor orients the second lateral edge toward the second commissure, while the distal ventricular anchor may optionally be mounted to the coaptation assist body prior to introduction into the patient and used to help orient the coaptation assist body. In many embodiments the coaptation assist body of the supported implant will define a curve extending across the blood flow path of the valve. The curve of the coaptation assist body can corresponding to the curve of the coaptation zone. Optionally, the engagement between the implant and the tissue of the heart may orient and maintain a position of the coaptation assist body so that the curves correspond. The implant will often be deployed and supported within the heart so that along the coaptation zone the first surface has a curved cross-section and the second surface has a curved cross-section, and so that coaptation assist body, including the curved cross-sections of the first and second surfaces, is separated from and curves around the central axis of the heart valve. The implant can be deployed and supported within the heart so that along the coaptation zone the first surface has a concave cross-section and the second surface has a convex cross-section, and so that the concave cross-section of the first surface is separated from and curves around the axis of the heart valve.
In another device aspect, a coaptation assist device for treating mal-coaptation of a heart valve in a patient is provided. The heart valve has an annulus and first and second leaflets. The annulus defines a valve axis, and the first and second leaflets have a coaptation zone. The device comprises a coaptation assist body having an axis and first and second opposed major coaptation surfaces. The coaptation assist body defines a channel within the coaptation assist body, and the coaptation assist body is introducible into the heart and coupleable in vivo within the heart valve. The device further comprises a tether disposed within the axial channel and coupled to the coaptation assist body near a first end of the channel, and also comprises a curvature lock attached to the tether near a second end of the channel. The tether is lockable by the lock to constrain the distance between the first and second ends of the channel so as to define a curvature of the coaptation assist body.
In another method aspect, a method of treating mal-coaptation of a heart valve in a patient is provided. The heart valve has an annulus and first and second leaflets. The annulus defines a valve axis extending along a blood flow path, and the first and second leaflets have a coaptation zone. The method comprises introducing an implant having a coaptation assist body with first and second opposed coaptation surfaces into the heart valve, supporting the deployed implant so that the coaptation assist body is disposed within the coaptation zone, and adjusting a curvature of the coaptation assist body.
In another system aspect, a system for treating mal-coaptation of a heart valve in a patient is provided. The heart valve has an annulus and first and second leaflets, and the annulus defines a valve axis. The system comprises a catheter system including a catheter body having a proximal end and a distal end, and the distal end is steerable within the heart from the proximal end. The system further comprises a coaptation assist body having an axis and first and second opposed major coaptation surfaces. Each of the coaptation surfaces extends laterally between a first lateral edge and a second lateral edge of the coaptation assist body. The coaptation assist body is introducible into the heart and coupleable in vivo within the heart valve, and the coaptation assist body defines a channel. The system further includes a tether extending through the channel such that a curvature of the coaptation assist body is adjustable by varying the distance between the ends of the channel along the tether. The system also comprises a curvature lock on the tether operable to constrain the distance between the ends of the channel so as to define a curvature of the coaptation assist body.
Advantageously, engagement between the implant and the heart valve (optionally including engagement between the coaptation assist body and the leaflets) can induce conformation of the curve of the coaptation assist body to the curve defined by the coaptation zone of the heart valve. More specifically, the coaptation zone of the heart valve may have a pre-treatment coaptation zone and the coaptation zone may exhibit a pre-treatment curve across the valve annulus. Engagement of the heart valve against the implant can laterally bend the coaptation assist body from a nominal cross-sectional shape toward the pre-treatment curve. Note that lateral flexibility of the coaptation assist body may be quite high (some embodiments relying on a single sheet of relatively thin membrane along at least a portion of the body, optionally with the membrane being supported at opposed edges and without lateral reinforcement against lateral bending), and that the bending forces will often be imposed at least in part via the anchoring structures (and/or via the direct engagement between the native leaflets of the valve and the coaptation assist body). Where the first leaflet may coapt with the first coaptation surface along a first axial coaptation range, and the second leaflet may coapt with the second coaptation surface along a second axial coaptation range at least partially offset from the first coaptation range, the coaptation assist body will preferably have sufficient axial stiffness to inhibit axial flexing when the first and second axial coaptation ranges are offset such that regurgitation associated with prolapse is inhibited. For example, axially oriented stiffeners may extend along an axial length of the coaptation body. In many embodiments, the axial stiffness of the coaptation assist body will be greater than a lateral stiffness of the coaptation assist body, such that engagement of the leaflets of the valve against the coaptation assist body laterally bends the coaptation assist body with limited axial bending of the coaptation assist body, optionally through the use of axial stiffeners, supporting of the coaptation assist body under an axial load, or the like.
Embodiments of the coaptation assist body and methods for its use may benefit from relatively simple and readily deployed shapes. In some embodiments, the implant can be deployed and supported within the heart so that downstream of the coaptation zone the coaptation assist body defines a downstream curve, the downstream curve having a radius smaller than the curve of the coaptation assist body along the coaptation zone this provides the coaptation assist body with a funnel-like shape. A lateral width of the coaptation assist body adjacent the annulus may be configured to extend only part way between the commissures during some or all of the heart beat cycle. As the commissure-to-commissure width of the valve may decrease significantly from diastole to systole, having the width of the coaptation assist body being less than the commissure-to-commissure width may help limit disadvantageous bending of the coaptation assist body during cardiac cycles. Some embodiments may employ coaptation assist bodies having a first lateral width adjacent the annulus that is configured for sealingly engaging against the valve at the first commissure and at the second commissure. The coaptation assist body of the supported implant can taper axially inwardly downstream of the coaptation zone so that a downstream width of the coaptation assist body is less than the first width, with the downstream end preferably being rigidly or resiliently supported by a third anchor deployed in the ventricle of the heart. Where the coaptation assist body comprises a conformable material such as ePTFE, such a triangular structure may be constrained in a relatively small diameter catheter and easily and accurately deployed within the valve using plastically deformable polymers or the like, often without having to rely on exotic resilient flexible structural shapes or being subject to fatigue failures related to the significant changes in size of the valve annulus during beating of the heart.
A variety of known or new support structures can be used to support the coaptation assist body within the valve of the heart. In exemplary embodiments, a first lateral edge of the coaptation assist body will be supported with a first support interface adjacent the first commissure. A second lateral edge of the coaptation assist body can similarly be supported with a second support interface adjacent the second commissure. Each of the first and second support interfaces should ideally be able to transmit loads between the coaptation assist body and tissue of the heart so as to maintain a desired position of the implant when the annulus of the heart changes in diameter by more than 10% with each beat of the heart, typically by more than 15%, and ideally by about 20% or more. While some embodiment may employ arcuate support structures extending around the valve annulus or structural interconnects which seek to resiliently or rigidly span the annulus (optionally so as press outwardly against opposed regions of the annulus during at least a portion of heart beat cycle), preferred approaches will avoid the limitations on cardiac tissue movement and/or limits to fatigue life of the implant that may result. By instead employing functionally separate anchor structures near each commissure, which anchors can be independently deployed (and if desired, independently removed and repositioned), these embodiments present significant structural advantages without having to limit tissue movement or implant life.
Exemplary embodiments of the structural interfaces supporting the coaptation assist body may include a tissue penetrating body that can be advanced from within a chamber of the heart into a tissue of the heart. For example, the interface may employ a helical body having a helical axis, so that advancing of the helical body into the tissue of the heart can be performed by rotating the helical body about the helical axis so as to screw the helical body into a tissue of the heart adjacent the annulus. When the interface relies on an annular support structure adjacent the annulus, at least one of the support interfaces may comprise a sliding interface between the annular support structure and the coaptation assist body so as to accommodate tissue motion without limiting fatigue life. An apical end of the coaptation assist body may extend axially from the annulus toward a ventricular apex of the heart, and the apical end of the coaptation assist body can be supported relative to a ventricular tissue of the heart with a ventricular support interface such as an anchor deployed between the papillary muscles. The apical end of the coaptation assist body can be affixed to a tissue-engaging surface of the anchor or other ventricular support interface, or a resilient (including superelastic) structure such as a spring, elastic fabric, metal coil, or the like may alternatively resiliently support the apical end of the coaptation assist body relative to a tissue engaging surface of the ventricular support interface so as to support the implant throughout changes in axial length of the ventricle during beating of the heart. Although optional embodiments might include a shaft or other structural member extending from tissues of the ventricle toward the atrium so as to axially maintain the coaptation assist body up within the coaptation zone, many embodiments can forego such compressively loaded structures.
The relative sizes and shapes of the coaptation assist bodies may be selected in response to characterization of the mal-coaptation of a particular patient's mitral valve, in response to valve measurements, and/or the like, but will often include certain common characteristics that enhance the functioning and/or deployment of the implant. When the implant is in a nominal configuration (such as when the coaptation assist device is unconstrained and at rest within blood or another suitable fluid) the coaptation assist body may have an axial length, a thickness between the coaptation surfaces, and a commissure-to-commissure width. Similarly, when the implant is deployed, coaptation assist device may similarly have an axial length, a thickness, and a width. When the implant is in the nominal and/or deployed configuration the width may be from 5 mm to 35 mm, typically being about 20 mm. Preferably, when the implant is in the nominal and/or deployed configuration the thickness will typically be from 0.5 mm to 10 mm, preferably being about 3 mm; and in many cases less than 20% of the width, often less than 15% of the width, optionally being less than 10% of the width. In many embodiments, when in the nominal and/or deployed configuration, the length will be from 20 mm to 60 mm, preferably being about 40 mm; and generally at least 75% of the width, typically being at least 150% of the width, and in many cases being at least 175% or even at least 200% of the width. The commissure-to-commissure width of the coaptation assist body can be less than a measured commissure-to-commissure width of the patient's valve during diastole or even slightly less than a measured commissure-to-commissure width of the valve during systole, such that the coaptation assist body fits within the valve without being excessively distorted or impinged upon along its lateral edges. Nonetheless, the width of the coaptation assist body will typically be adequate to induce sealing of the valve. In some cases, the coaptation assist body may be only a portion of a measured valve width, which could be as small as 75% or even 60%.
The implants described herein will often be deployable from a lumen of a trans septal or other atrial access catheter, an outer profile of the catheter deployment system typically being less than 19 Fr, often being less than 16 Fr, in many cases being 14 Fr or less. The coaptation assist body may be deployable by removing the coaptation assist body from within the surrounding deployment catheter and laterally expanding the coaptation assist body from an insertion profile to a deployed profile. The coaptation assist body may expand laterally by unfurling, unfolding, and/or unrolling the coaptation assist body. In some embodiments, the coaptation assist body has an insertion volume within the deployment catheter and a deployed volume greater than the insertion volume, with the body volumetrically expanding within the heart so as to increase a thickness of the coaptation assist device between the first and second coaptation surfaces after it is removed from the catheter lumen. The coaptation assist body may comprise a permeable material, and may be configured to volumetrically expand without resorting to inflating the coaptation assist body using inflation fluid introduced from outside a vascular system of the patient. In other embodiments, balloon-inflation like expansion may be used, or the coaptation assist body may have an insertion volume within the deployment catheter, and the implant may be configured so as to inhibit mal-coaptation without volumetrically expanding the coaptation assist body from the insertion volume. In some embodiments, and particularly where the mal-coaptation of the valve varies along the curve prior to implantation (for example, when there is prolapse of a segment of the mitral valve such as A2-P2), the variation in mal-coaptation along the curve may be characterized using imaging (such as ultrasound imaging, fluoroscopy, angiography, computer tomography, magnetic resonance imaging, or the like). A thickness of the deployed coaptation assist body between the first coaptation surface and the second coaptation surface may vary along the curve in response to the characterization of the variation in mal-coaptation, optionally by selecting of an appropriate valve body from among a plurality of alternative valve bodies in response to the characterization.
The use of at least partially independent anchors separated about the tissues of the heart and/or of mountingly coupling the valve body to the at least initially deployed anchors significantly facilitates implantation. Selectively deploying the first and second anchors may be performed by directing the first anchor toward the first target location, and directing the second' anchor (often after the first anchor has been at least initially deployed and independently of the directing of the first anchor) toward the second target location. The directing of the first anchor can be performed by steering a steerable catheter body from outside the patient, and the directing of the second anchor can be performed by steering the same steerable catheter body. The steerable catheter body may support an electrode sensing surface, and an electrogram may be sensed at candidate target locations when the electrode sensing surface is connected externally to an electrical signal recording device. Alternatively, the anchor itself may have electrical sensing capability and connected externally to an electrical signal recording device, or both catheter body and anchor may have electrical sensing capability. The first and/or second target locations can be sensed in response to the electrograms of the candidate target location, such as by determining when the electrogram has a desired signal corresponding to one or more of the major structures of the heart (for example, a desired mix of atrial and ventricle signals to identify axial positioning relative to the valve annulus, with or without a mix of signals indicative of lateral positioning relative to the septum or other anterior/posterior structures. Tactile indications of the annulus and commissures may also be employed, optionally under ultrasound and/or fluoroscopic imaging.
The separate deployment of the anchors may also facilitate verification that adequate support will be provided. For example, the first anchor may be configured to be initially deployed while remaining coupled to the deployment system, such as by keeping a torqueable body connected to a helical anchor after the anchor has been screwed into the heart tissue from within the heart. It will then be possible to determine that the initially deployed first anchor is not satisfactory, such as by applying tension to the connecting body, via electrogram signals transmitted from the anchor, or the like. The initially deployed first anchor can then be disengaged from tissue of the heart, aligned with the first target location, and re-deployed. It will then be relatively straightforward to verify that the first anchor deployment at the first target location is acceptable, and the initial deployment, moving, and verifying can all be performed without disengaging the second anchor from the second target location (either because it was not yet even initially deployed, or by leaving the second anchor in engagement with the target tissue throughout the process).
The coaptation assist body to be implanted in a particular patient may be selected from among a plurality of alternatively selectable coaptation assist bodies included with the implantation system. The alternative bodies may have differing geometries suitable for mitigating mal-coaptation of differing patients, and may be selected for implantation with the anchors into the patient, optionally after at least one of the first and second anchors are at least initially deployed, such as in response to a measurement of a location, separation, or other characteristic of the deployed first and second anchors. Some or all of the coaptation assist bodies may have flanges that protrude laterally from the coaptation surface when the coaptation assist bodies are in their nominal or deployed configurations, which the flanges often being configured so as to inhibit leaflet prolapse. The geometries of the flanges will often differ among the coaptation assist bodies so as to facilitate mitigation of differing leaflet prolapse characteristics of different patients by selecting an appropriate coaptation assist body for that patient, often in response to imaging or measurement of the heart. For example, flanges may protrude from the anterior and/or posterior coaptation surfaces, may have differing protrusion lengths, surface shapes, and/or axial positions, may have differing lateral widths and lateral positions, and the like.
The coaptation assist body may be supportingly coupled in vivo with the first and/or second anchors after the first and/or second anchors are initially deployed. A third anchor may be configured to be deployed at a third target location axially offset from the first and second target locations, optionally within the left ventricle such as a region of the ventricle of the heart between papillary muscles of the ventricle. The third anchor may be pre-mounted to the valve body, and or may otherwise be configured to be advanced within the deployment system toward the third target location after the first and second anchors are deployed, using either the same steerable catheter or a different steerable catheter. The third anchor can be rigidly affixed to an apical portion of the coaptation assist body, with the body configured to accommodate relative movement between the anchors during beating of the heart with deformation (such as lateral flexing and/or axial resilient elongation) of the coaptation assist body In some embodiments, an axially resilient structure and/or material such as a spring, a resilient polymer material such as a silicone elastomer, or the like may couple the third anchor to the apical portion of the coaptation assist body so as to accommodate the relative movement between the anchors. Still further options might be provide, including supporting the coaptation assist body with the third anchor via a tether coupling the third anchor to an apical portion of the coaptation assist body, and further comprising accommodating relative movement between the anchors during beating of the heart with resilient deformation of the coaptation assist body between the tether and the first and second anchors.
Advantageously, the devices and systems described herein can allow a physician to determine an effectiveness of the implant at mitigating the mal-coaptation while a delivery catheter remains coupled to at least one of the anchors and/or to the coaptation assist body. The catheter may remain coupled to the anchors such that the catheter system does not impose a significant load on the implant, such that the implant can be evaluated for effectiveness in substantially the position and configuration the implant will have once the catheter system is decoupled and removed. If the desired results are not seen, the physician can move and/or replace the coupled anchor, and/or can replace the coaptation assist body while leaving at least another of the anchors deployed. While some exemplary anchor embodiments use a tissue penetrating helical body having a helical axis configured for rotating the helical body about the helical axis so that helical body penetrates the first target location from within the heart, a variety of alternative anchors might be used. In some embodiments, the anchors might comprise suture, clips, staples, radiofrequency energy welds, or the like, and may be used to mount the body to heart tissue within the heart in an open surgical approach, during a robotic or endoscopic procedure, with access to the valve optionally being provided through a puncture or incision through the ventricular apex or atrial appendage, or the like. The implant will typically be configured so that, when deployed, loads transmitted between the coaptation assist body and tissue of the heart allow the annulus of the heart valve to change in diameter by more than 10% with each beat of the heart. Despite these significant size excursions, and despite the first and second anchors being circumferentially separated around the annulus, the anchors may each support the deployed implant sufficiently independently of the other to inhibit subjecting any resilient (including super-elastic) anchor-anchor interconnecting structure to fatigue-related failure during long-term implantation. Hence, the invention can be used as a mitral leaflet coaptation enhancement device configured to be positioned within the mitral valve during a brief, minimally invasive procedure, and can improve valve function without requiring reshaping of all or part of the mitral annulus, and without changing leaflet edge anatomy (such as by fusing leaflet edges or the like).
The present invention generally provides improved medical devices, systems, and methods, often for treatment of mitral valve regurgitation and other valve diseases. The implants described herein will generally include a coaptation assist body (sometimes referred to herein as a valve body) which is within the blood flow path as the leaflets of the valve move back and forth between an open-valve configuration (with the leaflets separated from valve body) and a closed-valve configuration (with the leaflets engaging opposed surfaces of the valve body). The valve body may structurally float or move within the annulus of the valve during beating of the heart, and will be disposed between the native leaflets to fill gaps between the coapting leaflet surfaces. Those gaps may be lateral (such as may be caused by a dilated left ventricle and/or mitral valve annulus) and/or axial (such as where one leaflet prolapses or is pushed by fluid pressure beyond the annulus when the valve should close.
Among other uses, the coaptation assistance devices, implants, and methods described herein may be configured for treating functional and/or degenerative mitral valve regurgitation (MR) by creating an artificial coaptation zone within which each of the native mitral valve leaflets can seal. The structures and methods herein will largely be tailored to this application, though alternative embodiments might be configured for use in other valves of the heart and/or body, including the tricuspid valve, valves of the peripheral vasculature, or the like.
Referring to
The fibrous annulus, part of the cardiac skeleton, provides attachment for the two leaflets of the mitral valve, referred to as the anterior leaflet and the posterior leaflet. The leaflets are axially supported by attachment to the chordae tendineae. The chordae, in turn, attach to one or both of the papillary muscles of the left ventricle. In a healthy heart, the chordae support structures tether the mitral valve leaflets, allowing the leaflets to open easily during diastole but to resist the high pressure developed during ventricular systole. In addition to the tethering effect of the support structure, the shape and tissue consistency of the leaflets helps promote an effective seal or coaptation. The leading edges of the anterior and posterior leaflet come together along a funnel-shaped zone of coaptation, with a lateral cross-section of the three-dimensional coaptation zone CZ being shown schematically in
Generally, mal-coaptation can result from either excessive tethering by the support structures of one or both leaflets, or from excessive stretching or tearing of the support structures. Other, less common causes include infection of the heart valve, congenital abnormalities, and trauma.
Valve malfunction can result from the chordae tendineae becoming stretched, known as mitral valve prolapse, and in some cases tearing of the chordae or papillary muscle, known as a flail leaflet. Or if the leaflet tissue itself is redundant, the valves may prolapse so that the level of coaptation occurs higher into the atrium, opening the valve higher in the atrium during ventricular systole. Either one of the leaflets can undergo prolapse or become flail. This condition is sometimes known as structural mitral valve regurgitation.
In excessive tethering, the leaflets of a normally structured valve may not function properly because of enlargement of or shape change in the valve annulus: so-called annular dilation. Such functional mitral regurgitation generally results from heart muscle failure. And the excessive volume load resulting from functional mitral regurgitation can itself exacerbate heart failure, ventricular and annular dilation, thus worsening mitral regurgitation.
The anterior and posterior mitral leaflets are dissimilarly shaped. The anterior leaflet is more firmly attached to the annulus overlying the central fibrous body (cardiac skeleton), and is somewhat stiffer than the posterior leaflet, which is attached to the more mobile posterior lateral mitral annulus. The coaptation zone between the leaflets is not a simple line, but rather a curved funnel-shaped surface interface. The commissures are where the anterior leaflet meets the posterior leaflet at the annulus. As seen most clearly in the axial views from the atrium of
Referring now to
Referring now to
Still referring
The deployed coaptation assist implants described herein may exhibit a number of desirable characteristics. Generally, the deployed implants will mitigate or help correct mitral regurgitation MR due to mal-coaptation, including mal-coaptation secondary to restricted leaflet motion (i.e., excessive tethering of the mitral support structures including the papillary muscles and chordae tendineae.) Similarly, the deployed implants may mitigate or help correct MR due to mal-coaptation secondary to excessive leaflet motion such as associated with mitral valve prolapse or flail leaflet. Exemplary embodiments need not rely on reshaping of the mitral annulus (such as by thermal shrinking of annular tissue, implantation of an annular ring prosthesis, and/or placement of a cinching mechanism either above or beneath the valve plane, or in the coronary sinus or related blood vessels). Advantageously, they also need not disrupt the leaflet structure or rely on locking together or fusing of the mitral leaflets. Many embodiments can avoid reliance on ventricular reshaping, and after implantation represent passive implanted devices with limited excursion which may results in an very long fatigue life. Mitigation of mitral valve mal-coaptation may be effective irrespective of which leaflet segment(s) exhibit mal-coaptation. The treatments described herein will make use of implants that are repositionable during the procedure, and even removable after complete deployment and/or tissue response begins or is completed, often without damaging the valve structure. Nonetheless, the implants described herein may be combined with one or more therapies that do rely on one or more of the attributes described above as being obviated. The implants themselves can exhibit benign tissue healing and rapid endothelialization which inhibit migration, thromboembolism, infection, and/or erosion. In some cases, the coaptation assist body will exhibit no endotheliazation but its surface will remain inert, which can also inhibit migration, thromboembolism, infection and/or erosion.
Referring now to
Referring still to
Referring now to
Valve body 122 in its nominal or deployed configuration may have an atrial or proximal end 134 and a ventricular or distal end 136, as seen in
As seen in
Referring now to FIGS. 3G1 and 3G2, schematic axial cross-sections of valve body 122 show an outer tissue ingrowth layer 170 disposed along the opposed major surfaces 156, 158 over a fluid-absorbing core 172. Core 172 can have a small volume configuration prior to implantation (as shown in FIG. 3G2) in which the core has a significantly smaller volume than after core 172 has been deployed within the heart and absorbed fluid. Suitable materials for core 172 may comprise foams including medical grade polyurethane foam, silicone and/or natural rubber foam, hydrogels, a wide variety of hydrophilic polymer matrices, or the like. Core 172 and outer layer 170 may together define a nominal cross-sectional shape of the valve body (including a valve body curve 174) when the valve is unconstrained and absorbs blood or another suitable model fluid. As the valve body will often be a relatively conformable structure with a geometry that can be altered by interaction with tissues, the deployed cross-sectional shape of the valve body (and the overall three-dimensional valve body shape) will often depend on both the nominal shape, the surrounding cardiac tissue, and the characteristics (locations and the like) of the anchors.
Referring now to
Referring now to FIGS. 3I3-3I2, an exemplary anchor deployment assembly 402 includes an anchor coupling body 110 and the associated anchor 108, along with an anchor deployment catheter 404. Anchor deployment catheter 404 includes an elongate shaft with a proximal portion 406 extending distally to a more flexible distal portion 408. A distal tip of the flexible portion includes a torque-imparting feature such as a slot 410 to releasably rotationally drive anchor 108 when a transverse member across the helical coil of the anchor axially engages the distal end of anchor deployment catheter (such as when the elongate coupling body 110 proximal of anchor catheter 404 is pulled proximally), allowing the anchor to be rotationally and axially driven into tissue by manipulating the proximal end of the anchor deployment catheter.
The structure and use of an exemplary anchor crimping and cutting assembly 420 can be understood with reference to FIGS. 3I6-3I9. A crimping and cutting catheter 422 includes a shaft 424 that extends distally from a proximal handle 426. A distal portion of shaft 424 is more flexible than a proximal portion, and ends at a distal tip 428 having a side port 430 and releasably supporting a crimp 432. Crimp 432 receives anchor coupling body 110 therethrough, with crimp features configured (such as by being biased radially inwardly, having proximally oriented edges, and/or the like) to allow the coupling body to slide proximally through the crimp but to inhibit distal movement of the coupling body relative to the crimp. A distally oriented surface of crimping and removal catheter 420 engages the crimp, allowing the crimp to be advanced distally along the coupling body 110 by pushing handle 426 distally and/or pulling the coupling body from outside the patient. Once crimp 432 engages (or is sufficiently close to) anchor 108, a cutting knob 434 adjacent handle 426 can be actuated so as to advance a cutting member such as a blade 440 and sever elongate body 110 adjacent anchor 108, as can be understood with reference to FIGS. 3I7 and 3I8. Crimping and cutting catheter 420 can then be decoupled from crimp 432 and anchor 108 by withdrawing the handle proximally, as shown in FIG. 3I9. Note that crimp 432 will often be used to affix an implant to anchor 108 by advancing the implant over the coupling body 110 prior to advancing 432 distally.
An alternative crimping and cutting assembly 420′ and associated method can be understood with reference to FIGS. 3I10-3I13, with the assembly here having an alternative cutting member 440′ coupled to an energy source 444. Energy source 444 may comprise an ultrasound energy source, a laser energy source, an RF or other electrical energy source, or the like, so that energizing of the cutting member by the energy source facilitates decoupling of the elongate body 110 from the anchor. Note that a wide variety of alternative decoupling and/or cutting systems might be employed, including systems derived from those used to decouple embolism coils and the like. Similarly, a variety of crimping or other anchor/valve body coupling mechanisms may be employed, and a separate crimp catheter structure and cutting catheter structure could be used if desired.
Referring now to FIGS. 3I14-3I17, it can be seen how an aperture through lateral atrial support 140 can be disposed over elongate connector bodies 110 between the anchors 108 and crimps 432, capturing the atrial support and thereby providing a coupler 182 that mounts the valve body 122 to the anchors. Additional details regarding an exemplary ventricular coupler 182 that can be used to affix the ventricular portion of coaptation body 122 to the ventricular anchor 108 can also be seen. More specifically, a hub 450 includes an outer collar and a pin 452 extending laterally therethrough. Ventricular anchor 108 extends axially through hub 450, with the helical winds of the anchor passing above and below pin 452. A torquable feature such as a socket 454 removably engages a driving feature 456, allowing an anchor deployment shaft 458 to rotate the helical anchor from outside the patient through a delivery catheter or sheath 128. As can be understood by comparing the ventricular anchors of FIGS. 3I17 and 3I18, interaction between pin 452 of hub 450 and the helical coils of anchor 108 during rotation of the anchor drives the anchor distally, facilitating advancement into tissue of the ventricle.
Referring now to FIG. 3I18, an implant having an alternative and optionally less traumatic ventricular anchor 460 is shown. Anchor 460 comprises a central shaft 462 and a circumferential array of radially protruding arms 464, with the arms angling proximally when in a nominal or deployed configuration. Arms 464 of anchor 460 may be resiliently compressed inwardly for delivery or advancement within tissue of the ventricle, with the arms optionally retaining the anchor in the heart tissue like barbs, with the arm structures comprising a relatively high strength metal such as a Nitinol alloy, or a high strength polymer. In exemplary embodiments, anchor 460 need not penetrate deeply into the tissue of the heart wall, but can be advanced so that arms 464 less traumatically entangle with the ventricular trabeculae. Such embodiments may employ relatively flexible arm materials and configurations, with the arms optionally comprising relatively soft tines of a polymer such as polyurethane, polyester, nylon, or the like.
Referring now to
Referring now to
Referring now to
Still further alternative or additional anchor structures and structural interface approaches may be employed. An arcuate support base 202 may be configured to extend along the annulus of the valve for alternative implant 204 as shown in
The coaptation assistance devices described herein are often configured for transvascular delivery and/or deployment via minimally invasive surgery (e.g. thoracotomy, transapical, via the left atrial appendage (LAA), or the like), with delivery and placement preferably being in between or adjacent to the cardiac valve's native leaflets. In particular, the valve can be one of the AV valves such as the tricuspid valve and/or the mitral valve. The drawings and exemplary embodiments largely relate to the mitral valve, but analogous methods and devices can be applied to the tricuspid valve. The coaptation assistance body of the implant can often be delivered by a delivery catheter and may be capable of expanding from a smaller profile to a larger profile to dimensions appropriate for placement in between the valve's native leaflets. In some embodiments, the implants may also find applications for treatment of nonnative valve leaflets (for example, after valve replacement) or for treatment after the native leaflets have previously been surgically modified.
The leaflet-apposing valve body element may comprise self expandable materials such as medical grade polyurethane foam and may be covered with a material such as ePTFE. The valve body may optionally include or be affixed to (or otherwise mountable on) a self expandable frame, with the frame optionally comprising a plurality of members including resiliently (including super-elastically) deformable materials such as a Nitinol alloy. Other frame materials may include stainless steel, plastics, etc. Other materials for the covering include polyurethanes, biologic tissue such as porcine pericardium, silicone, etc. In other embodiments, the leaflet-apposing valve body element may comprise a self-expandable structure such as a Nitinol alloy frame and covered with biocompatible material such as ePTFE. In yet other embodiments the leaflet-apposing element and/or the support interfaces may comprise a braided structure appropriately shaped and covered with ePTFE to fill the gap between the incompetent (mal-coapting) leaflets.
The entire implant and/or valve body, or portions thereof, may incorporate a radiopaque material or an echo-enhancement material for better visualization. The leaflet-apposing valve body element may have a symmetrical or asymmetrical cross section to create an optimal coaptation surface, with the cross-section preferably corresponding to (and/or depending on) the anatomy of the leaflets and their mal-coaptation. The leaflet apposing valve body element may include a curve biased toward a prolapsing leaflet to provide structural support for the prolapsing leaflet and inhibit prolapsing of the leaflet so as to mitigate mal-coaptation. The leaflet apposing valve body element may be printed with a radio-opaque material such as radio-opaque ink. Any support structures of the valve body or support interface having a frame may be coated with radio-opaque materials such as gold or platinum or impregnated with barium. The leaflet apposing valve body element may be coated with an echo enhancement material.
The coaptation assistance device or implant may include one or a plurality of atrial anchors to stabilize the device and/or a ventricular anchor, with the anchors optionally providing redundant fixation. The atrial anchor or anchors may attach to or adjacent the annulus. The annular anchor, if it is included, may be covered with biocompatible materials such as ePTFE to promote endothelialization and, optionally, chronic tissue in-growth or encapsulation of the annular anchor for additional stability. Furthermore the annular anchor may include a plurality of barbs for acute fixation to the surrounding tissue. In other embodiments, the atrial anchors may comprise a plurality of helixes, clips, harpoon or barb-shaped anchors, or the like, appropriate for screwing or engaging into the annulus of the mitral valve, tissues of the ventricle, and/or other tissues of the atrium, or the atrial or ventricular anchors may attach to the tissue by welding using RF energy delivered via the elongate anchor coupling body 110. The ventricular anchor may comprise a helix rotatable with respect to the leaflet apposing element and connected to the hub of the leaflet apposing element by a suture or ePTFE tube. In some embodiments, a ventricular anchor may be included in the form of a tether or other attachment means extending from the valve body thru the ventricle septum to the right ventricle, or thru the apex into the epicardium or pericardium, which may be secured from outside the heart in and combined endo/epi procedure. When helical anchors are used, they may comprise bio-inert materials such as Platinum/Ir, a Nitinol alloy, and/or stainless steel. As noted above, in some embodiments, an atrial anchor in the form of an expandable structure for placement in the left atrial appendage may be included. In still further embodiments, an atrial anchor and support interface may be included in the form of a flexible line or tether attached to an atrial septal anchor. The atrial septal anchor may be configured like a transseptal closure device, optionally using structures that are well known. Any left atrial appendage anchor or atrial septal anchor may be covered with a biocompatible material such as ePTFE, silicone, Dacron, or biologic tissue, or fixed in place using RF welding. A left atrial appendage anchor or atrial septal anchor may be connected to the leaflet apposing valve body element with suture, or ePTFE tube, or may comprise a pre-shaped and rigid or resilient material such as a Nitinol alloy.
The delivery system may include a delivery catheter, with exemplary delivery catheters comprising a variable stiffness shaft with at least one through lumen, the shaft configured for deflecting along at least a distal section. The delivery catheter may further include a control handle to manipulate the device anchors and to manipulate the docking and undocking of the device with the delivery catheter. The control handle may further include flush, irrigation and aspiration ports to remove the air from the system and allow injection of fluids such as saline or contrast media to the site of implantation. The delivery system may also include at least one torque shaft or other elongate anchor coupling body for manipulating the device anchors, initially deploying and recapturing of the anchors to and from the delivery catheter, and guiding the valve body distally to one or more of the initially deployed anchors.
The delivery system may also include an outer sheath or introducer, typically to allow the introduction of the delivery catheter through a lumen of the outer sheath and into the left atrium, so that the outer sheath functions as a trans septal sheath. The transseptal sheath may include a variable stiffness outer shaft with at least one lumen, the lumen sized to allow insertion of the delivery catheter and/or coaptation assistance body through the sheath lumen. A deflectable distal section of the trans septal sheath may facilitate alignment of the coaptation assistance device with the valve leaflets.
A conductive surface of the catheter system and/or implant may be coupled by a conductor to a proximal end of the delivery system so as to allow the conductive surface to act as an electrode, for example, to help to detect the location and/or deployment characteristics of an implant. The transseptal catheter and/or delivery catheter may include at least one electrode at the distal tip configured to be connected to an intracardiac electrogram sensing and/or recording system. In some embodiments, an electrogram may be sensed from the anchor 108, providing an electrogram signal that can be transmitted along the elongate anchor coupling body 110. Anchor coupling body 110 can be coupled with an appropriate electrogram recording system. Unipolar electrogram signals sensed at the electrode on the distal end or the delivery catheter, a unipolar electrogram sensed at the anchor 108, and/or a bipolar electrogram recorded between the delivery catheter electrode and the anchor, can be used to evaluate candidate locations for deployment of the anchor or other implant components. In particular the annulus of the valve may be detected by an appropriate ratio of atrial electrogram signals to ventricular electrogram signals at a candidate location. Once a signal ratio in a desired range has been identified (for example, with a ratio of about 1:2), the information from the signal may be combined with imaging information showing that the candidate location is near a commissure of the annulus, and in response, the candidate sight may be selected as an anchoring site for an associated atrial anchor.
Referring now to
Referring first to
Referring now to
As can be understood with reference to
Referring now to
Referring now to
As can be understood with reference to
Advantageously, hemodynamic performance of the valve with the valve body therein can be evaluated before decoupling one or more of the anchors from the delivery catheter system (and in some embodiments, even before the ventricle anchor is deployed in ventricle tissue). If results are less than desired, one or more of the anchors can be detached from the tissue and retracted back into the transseptal sheath 310, allowing the physician to reposition the anchor and coaptation assistance body. The valve body can be withdrawn proximally via sheath 310 and an alternative valve body selected, loaded into the sheath, and deployed if appropriate. One or more of the atrial and/or ventricular anchors can be redeployed and the surgical staff can again perform a hemodynamic evaluation. In some embodiments, one or more of guidewire 330 and/or elongate anchor deployment bodies 110, 110′ may remain coupled to an associated anchor for hours or even days. Once the implant is in the desired deployed configuration, the device may be locked to the elongate anchor deployment bodies or tethers using crimps, or knots, etc., and the excess lengths of these bodies may be cut and removed from the implant. In the exemplary embodiments, crimps 432 can be advanced distally using one or more crimping and cutting assembly 420 or 420′ so as to affix the valve body to the deployed atrial anchors, and elongate bodies 110 can be decoupled from the anchors, as can be understood with reference to
A full hemodynamic evaluation—e.g. intra cardiac echocardiogram (ICE), trans esophageal echocardiogram (TEE) or transthoracic echocardiogram (TIE) may be performed on the patient after deployment is complete.
Referring now to
Additional aspects of the present invention can be understood with reference to
Still further aspects of the present invention can be understood with reference to
As is visible
Referring again to
An effect of the adjustment of the curvature of coaptation assist body 901 is shown in
In other embodiments, a system and method are provided for treating mal-coaptation of a heart valve in a patient. The system may include a coaptation assist device such as or similar to coaptation assist device 900, in conjunction with a catheter system through which the coaptation assist device may be deployed within the heart valve.
In an exemplary method of treating mal-coaptation of a heart valve in a patient, an implant, for example coaptation assist device 900, is introduced into the heart valve. The introduction may be through a catheter system as described above. For example, the catheter system may include a guide catheter or sheath such as sheath 301, and one or more delivery catheters for delivering the coaptation assist body, anchors, and other items into the heart. In one application, a coaptation assist body such as coaptation assist body 901 is positioned in the coaptation zone between the anterior and posterior leaflets of the mitral valve. The coaptation assist body may be introduced in a first configuration and deployed in a second configuration. For example, the coaptation assist body may be furled for travel through the catheter system, and unfurled for deployment within the heart valve. The method may include anchoring an upstream end of the coaptation assist body to the annulus of the heart valve, and may also include anchoring the downstream end of the coaptation assist body to ventricular tissue of the heart.
Once the coaptation assist body is disposed within the heart valve, its curvature may be adjusted. For example, once the atrial and ventricular anchors are in place, a crimp delivery catheter may be advanced into the heart and a tether such as tether 905 may be tensioned to cause the curvature of the coaptation assist body to change by changing the distance between the upstream and downstream ends of the coaptation assist body. Once the desired curvature is set, a lock such as crimp 1001 may be engaged to constrain the distance between the upstream and downstream ends of the coaptation assist body. When the installation is complete, the excess tether may then be cut away, and the catheter system removed. The crimping and cutting may be accomplished in a manner similar to that discussed above and illustrated in FIGS. 3I6-3I9.
Preferably, the surgeon implanting the device is provided with sensory information about the beating heart during at least part of the installation of the coaptation assist device. For example, an echocardiogram may provide feedback as to the amount of valve regurgitation that is occurring, so that the surgeon can select the optimum amount of curvature of the coaptation assist body to mitigate, minimize, or eliminate the regurgitation.
While exemplary embodiments have been described in some detail for clarity of understanding, a variety of adaptations and modification will be clear to those of skill in the art. For example, access to the left atrium can be provided at least in part via a minimally invasive entry in the left atrial appendage or thru the left ventricular apex. Additionally, as the devices and methods described herein may be faster, less skill dependent, and/or suitable for sicker patients than alternative valve treatments (that often involve larger access systems or are otherwise more traumatic), and as the implants described herein may be temporarily deployed, these techniques may be used as a short or intermediate-term therapy, giving patients time and allowing recovery so as to be better able to tolerate an alternative treatment. These techniques may also be suitable for re-treatment of patients that have previously had valve therapies. These techniques may also be appropriate for placement in positions at the mitral valve in a patient undergoing coronary artery bypass grafting. Hence, the scope of the present invention is limited solely by the following claims.
This application is a continuation of U.S. patent application Ser. No. 16/675,565, filed Nov. 6, 2019, which in turn is a continuation of U.S. patent application Ser. No. 15/475,629, filed Mar. 31, 2017, now U.S. Pat. No. 10,470,883, which in turn is a continuation of U.S. patent application Ser. No. 14/500,470, filed Sep. 29, 2014, now U.S. Pat. No. 9,610,163, which in turn is a continuation of U.S. patent application Ser. No. 13/099,532, filed May 3, 2011, now U.S. Pat. No. 8,845,717, which in turn claims priority to provisional U.S. Patent Application No. 61/437,397, titled “Coaptation Enhancement Implant, System, and Method” and filed Jan. 28, 2011. The entire disclosure of each of the foregoing priority applications is hereby incorporated by reference herein for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3491376 | Shiley | Jan 1970 | A |
| 3503079 | Smith | Mar 1970 | A |
| 3656185 | Carpentier | Apr 1972 | A |
| 3671979 | Moulopoulos | Jun 1972 | A |
| 3874388 | King et al. | Apr 1975 | A |
| 3898701 | La Russa | Aug 1975 | A |
| 3938197 | Milo | Feb 1976 | A |
| 4007743 | Blake | Feb 1977 | A |
| 4011601 | Clune et al. | Mar 1977 | A |
| 4042979 | Angell | Aug 1977 | A |
| 4078268 | Possis | Mar 1978 | A |
| 4204283 | Bellhouse et al. | May 1980 | A |
| 4218783 | Reul et al. | Aug 1980 | A |
| 4261342 | Aranguren Duo | Apr 1981 | A |
| 4263680 | Ruel et al. | Apr 1981 | A |
| 4275469 | Gabbay | Jun 1981 | A |
| RE31040 | Possis | Sep 1982 | E |
| 4352211 | Parravicini | Oct 1982 | A |
| 4488318 | Kaster | Dec 1984 | A |
| 4490859 | Black et al. | Jan 1985 | A |
| 4491986 | Gabbay | Jan 1985 | A |
| 4561129 | Arpesella | Dec 1985 | A |
| 4687483 | Fisher et al. | Aug 1987 | A |
| 4705516 | Barone et al. | Nov 1987 | A |
| 4759758 | Gabbay | Jul 1988 | A |
| 4790843 | Carpentier et al. | Dec 1988 | A |
| 4960424 | Grooters | Oct 1990 | A |
| 4994077 | Dobben | Feb 1991 | A |
| 5002567 | Bona et al. | Mar 1991 | A |
| 5078737 | Bona et al. | Jan 1992 | A |
| 5131905 | Grooters | Jul 1992 | A |
| 5197980 | Gorshkov et al. | Mar 1993 | A |
| 5217484 | Marks | Jun 1993 | A |
| 5258023 | Reger | Nov 1993 | A |
| 5332402 | Teitelbaum | Jul 1994 | A |
| 5344442 | Deac | Sep 1994 | A |
| 5370662 | Stone et al. | Dec 1994 | A |
| 5397347 | Cuilleron et al. | Mar 1995 | A |
| 5397348 | Campbell et al. | Mar 1995 | A |
| 5413599 | Imachi et al. | May 1995 | A |
| 5487760 | Villafana | Jan 1996 | A |
| 5500015 | Deac | Mar 1996 | A |
| 5522886 | Milo | Jun 1996 | A |
| 5554186 | Guo et al. | Sep 1996 | A |
| 5582616 | Bolduc et al. | Dec 1996 | A |
| 5593435 | Carpentier et al. | Jan 1997 | A |
| 5626613 | Schmieding | May 1997 | A |
| 5658313 | Thal | Aug 1997 | A |
| 5662683 | Kay | Sep 1997 | A |
| 5662704 | Gross | Sep 1997 | A |
| 5716370 | Williamson, IV et al. | Feb 1998 | A |
| 5733331 | Peredo | Mar 1998 | A |
| 5824065 | Gross | Oct 1998 | A |
| 5824066 | Gross | Oct 1998 | A |
| 5824067 | Gross | Oct 1998 | A |
| 5855601 | Bessler et al. | Jan 1999 | A |
| 5888240 | Carpentier et al. | Mar 1999 | A |
| 5957949 | Leonhardt et al. | Sep 1999 | A |
| 6007577 | Vanney et al. | Dec 1999 | A |
| 6024096 | Buckberg | Feb 2000 | A |
| 6042607 | Williamson, IV et al. | Mar 2000 | A |
| 6045497 | Schweich et al. | Apr 2000 | A |
| 6045573 | Wenstrom et al. | Apr 2000 | A |
| 6063114 | Nash et al. | May 2000 | A |
| 6066160 | Colvin et al. | May 2000 | A |
| 6086612 | Jansen | Jul 2000 | A |
| 6113631 | Jansen | Sep 2000 | A |
| 6162233 | Williamson, IV et al. | Dec 2000 | A |
| 6217610 | Carpentier et al. | Apr 2001 | B1 |
| 6221104 | Buckberg et al. | Apr 2001 | B1 |
| 6250308 | Cox | Jun 2001 | B1 |
| 6264602 | Mortier et al. | Jul 2001 | B1 |
| 6287339 | Vazquez et al. | Sep 2001 | B1 |
| 6296662 | Caffey | Oct 2001 | B1 |
| 6299637 | Shaolian et al. | Oct 2001 | B1 |
| 6312447 | Grimes | Nov 2001 | B1 |
| 6312464 | Navia | Nov 2001 | B1 |
| 6332893 | Mortier et al. | Dec 2001 | B1 |
| 6358277 | Duran | Mar 2002 | B1 |
| 6383147 | Stobie | May 2002 | B1 |
| 6391053 | Brendzel et al. | May 2002 | B1 |
| 6391054 | Carpentier et al. | May 2002 | B2 |
| 6402679 | Mortier et al. | Jun 2002 | B1 |
| 6402780 | Williamson, IV et al. | Jun 2002 | B2 |
| 6409758 | Stobie et al. | Jun 2002 | B2 |
| 6419695 | Gabbay | Jul 2002 | B1 |
| 6439237 | Buckberg et al. | Aug 2002 | B1 |
| 6450171 | Buckberg et al. | Sep 2002 | B1 |
| 6451024 | Thompson et al. | Sep 2002 | B1 |
| 6454799 | Schreck | Sep 2002 | B1 |
| 6458153 | Bailey et al. | Oct 2002 | B1 |
| 6482228 | Norred | Nov 2002 | B1 |
| 6540782 | Snyders | Apr 2003 | B1 |
| 6544167 | Buckberg et al. | Apr 2003 | B2 |
| 6565603 | Cox | May 2003 | B2 |
| 6569198 | Wilson | May 2003 | B1 |
| 6602288 | Cosgrove et al. | Aug 2003 | B1 |
| 6602289 | Colvin et al. | Aug 2003 | B1 |
| 6626930 | Allen et al. | Sep 2003 | B1 |
| 6629534 | Goar et al. | Oct 2003 | B1 |
| 6652578 | Bailey et al. | Nov 2003 | B2 |
| 6676698 | McGuckin, Jr. et al. | Jan 2004 | B2 |
| 6682559 | Myers et al. | Jan 2004 | B2 |
| 6702852 | Stobie et al. | Mar 2004 | B2 |
| 6719790 | Brendzel et al. | Apr 2004 | B2 |
| 6752813 | Goldfarb et al. | Jun 2004 | B2 |
| 6764510 | Vidlund et al. | Jul 2004 | B2 |
| 6780200 | Jansen | Aug 2004 | B2 |
| 6790237 | Stinson | Sep 2004 | B2 |
| 6797002 | Spence et al. | Sep 2004 | B2 |
| 6800090 | Alferness et al. | Oct 2004 | B2 |
| 6805710 | Bolling et al. | Oct 2004 | B2 |
| 6821297 | Snyders | Nov 2004 | B2 |
| 6837247 | Buckberg et al. | Jan 2005 | B2 |
| 6840246 | Downing | Jan 2005 | B2 |
| 6846324 | Stobie | Jan 2005 | B2 |
| 6869444 | Gabbay | Mar 2005 | B2 |
| 6908478 | Alferness et al. | Jun 2005 | B2 |
| 6911043 | Myers et al. | Jun 2005 | B2 |
| 6926730 | Nguyen et al. | Aug 2005 | B1 |
| 6966925 | Stobie | Nov 2005 | B2 |
| 6991649 | Sievers | Jan 2006 | B2 |
| 6997950 | Chawla | Feb 2006 | B2 |
| 7018408 | Bailey et al. | Mar 2006 | B2 |
| 7037333 | Myers et al. | May 2006 | B2 |
| 7048754 | Martin et al. | May 2006 | B2 |
| 7056280 | Buckberg et al. | Jun 2006 | B2 |
| 7070618 | Streeter | Jul 2006 | B2 |
| 7077861 | Spence | Jul 2006 | B2 |
| 7077862 | Vidlund et al. | Jul 2006 | B2 |
| 7083628 | Bachman | Aug 2006 | B2 |
| 7087064 | Hyde | Aug 2006 | B1 |
| 7112207 | Allen et al. | Sep 2006 | B2 |
| 7122043 | Greenhalgh et al. | Oct 2006 | B2 |
| 7160322 | Gabbay | Jan 2007 | B2 |
| 7166126 | Spence et al. | Jan 2007 | B2 |
| 7175656 | Khairkhahan | Feb 2007 | B2 |
| 7195641 | Palmaz et al. | Mar 2007 | B2 |
| 7217284 | Houser et al. | May 2007 | B2 |
| 7226467 | Lucatero et al. | Jun 2007 | B2 |
| 7275546 | Buckberg et al. | Oct 2007 | B2 |
| 7291168 | Macoviak et al. | Nov 2007 | B2 |
| 7294148 | McCarthy | Nov 2007 | B2 |
| 7296577 | Taylor et al. | Nov 2007 | B2 |
| 7316706 | Bloom et al. | Jan 2008 | B2 |
| 7320704 | Lashinski et al. | Jan 2008 | B2 |
| 7335213 | Hyde et al. | Feb 2008 | B1 |
| 7338520 | Bailey et al. | Mar 2008 | B2 |
| 7341584 | Starkey | Mar 2008 | B1 |
| 7357814 | Gabbay | Apr 2008 | B2 |
| 7374572 | Gabbay | May 2008 | B2 |
| RE40377 | Williamson, IV et al. | Jun 2008 | E |
| 7381220 | Macoviak et al. | Jun 2008 | B2 |
| 7396364 | Moaddeb et al. | Jul 2008 | B2 |
| 7404824 | Webler et al. | Jul 2008 | B1 |
| 7435257 | Lashinski et al. | Oct 2008 | B2 |
| 7445630 | Lashinski et al. | Nov 2008 | B2 |
| 7455689 | Johnson | Nov 2008 | B2 |
| 7485143 | Webler et al. | Feb 2009 | B2 |
| 7510573 | Gabbay | Mar 2009 | B2 |
| 7510576 | Langberg et al. | Mar 2009 | B2 |
| 7527646 | Rahdert et al. | May 2009 | B2 |
| 7527647 | Spence | May 2009 | B2 |
| 7530998 | Starkey | May 2009 | B1 |
| 7534259 | Lashinski et al. | May 2009 | B2 |
| 7556645 | Lashinski et al. | Jul 2009 | B2 |
| 7559936 | Levine | Jul 2009 | B2 |
| 7563267 | Goldfarb et al. | Jul 2009 | B2 |
| 7563273 | Goldfarb et al. | Jul 2009 | B2 |
| 7591847 | Navia et al. | Sep 2009 | B2 |
| 7608091 | Goldfarb et al. | Oct 2009 | B2 |
| 7611534 | Kapadia et al. | Nov 2009 | B2 |
| 7621948 | Herrmann et al. | Nov 2009 | B2 |
| 7648532 | Greenhalgh et al. | Jan 2010 | B2 |
| 7655015 | Goldfarb et al. | Feb 2010 | B2 |
| 7658762 | Lashinski et al. | Feb 2010 | B2 |
| 7658763 | Stobie | Feb 2010 | B2 |
| 7666224 | Vidlund et al. | Feb 2010 | B2 |
| 7674286 | Alfieri et al. | Mar 2010 | B2 |
| 7678145 | Vidlund et al. | Mar 2010 | B2 |
| 7682391 | Johnson | Mar 2010 | B2 |
| 7691144 | Chang et al. | Apr 2010 | B2 |
| 7699892 | Rafiee et al. | Apr 2010 | B2 |
| 7704269 | St. Goar et al. | Apr 2010 | B2 |
| 7704277 | Zakay et al. | Apr 2010 | B2 |
| 7736388 | Goldfarb et al. | Jun 2010 | B2 |
| 7740638 | Hyde | Jun 2010 | B2 |
| 7744609 | Allen et al. | Jun 2010 | B2 |
| 7753923 | St. Goar et al. | Jul 2010 | B2 |
| 7758491 | Buckner et al. | Jul 2010 | B2 |
| 7758595 | Allen et al. | Jul 2010 | B2 |
| 7776084 | Johnson | Aug 2010 | B2 |
| 7785366 | Maurer et al. | Aug 2010 | B2 |
| 7799038 | Sogard et al. | Sep 2010 | B2 |
| 7803187 | Hauser | Sep 2010 | B2 |
| 7819915 | Stobie et al. | Oct 2010 | B2 |
| 7846203 | Cribier | Dec 2010 | B2 |
| 7887552 | Bachman | Feb 2011 | B2 |
| 7901454 | Kapadia et al. | Mar 2011 | B2 |
| 7909866 | Stobie | Mar 2011 | B2 |
| 7914576 | Navia et al. | Mar 2011 | B2 |
| 7927370 | Webler et al. | Apr 2011 | B2 |
| 7935144 | Robin et al. | May 2011 | B2 |
| 7935145 | Alfieri et al. | May 2011 | B2 |
| 7938827 | Hauck et al. | May 2011 | B2 |
| 7942928 | Webler et al. | May 2011 | B2 |
| 7951195 | Antonsson et al. | May 2011 | B2 |
| 7951196 | McCarthy | May 2011 | B2 |
| 7955385 | Crittenden | Jun 2011 | B2 |
| 7959673 | Carpentier et al. | Jun 2011 | B2 |
| 7981139 | Martin et al. | Jul 2011 | B2 |
| 7988725 | Gross et al. | Aug 2011 | B2 |
| 7993396 | McCarthy | Aug 2011 | B2 |
| 7998151 | St. Goar et al. | Aug 2011 | B2 |
| 8012201 | Lashinski et al. | Sep 2011 | B2 |
| 8012202 | Alameddine | Sep 2011 | B2 |
| 8016882 | Macoviak et al. | Sep 2011 | B2 |
| 8029518 | Goldfarb et al. | Oct 2011 | B2 |
| 8052751 | Aklog et al. | Nov 2011 | B2 |
| 8057493 | Goldfarb et al. | Nov 2011 | B2 |
| 8062355 | Figulla et al. | Nov 2011 | B2 |
| 8070804 | Hyde et al. | Dec 2011 | B2 |
| 8070805 | Vidlund et al. | Dec 2011 | B2 |
| 8092525 | Eliasen et al. | Jan 2012 | B2 |
| 8118866 | Herrmann et al. | Feb 2012 | B2 |
| 8128691 | Keranen | Mar 2012 | B2 |
| 8133272 | Hyde | Mar 2012 | B2 |
| 8142494 | Rahdert et al. | Mar 2012 | B2 |
| 8142495 | Hasenkam et al. | Mar 2012 | B2 |
| 8147542 | Maisano et al. | Apr 2012 | B2 |
| 8152844 | Rao et al. | Apr 2012 | B2 |
| 8163013 | Machold et al. | Apr 2012 | B2 |
| 8187207 | Machold et al. | May 2012 | B2 |
| 8187299 | Goldfarb et al. | May 2012 | B2 |
| 8187323 | Mortier et al. | May 2012 | B2 |
| 8204605 | Hastings et al. | Jun 2012 | B2 |
| 8206439 | Gomez Duran | Jun 2012 | B2 |
| 8216230 | Hauck et al. | Jul 2012 | B2 |
| 8216256 | Raschdorf, Jr. et al. | Jul 2012 | B2 |
| 8216302 | Wilson et al. | Jul 2012 | B2 |
| 8216303 | Navia | Jul 2012 | B2 |
| 8221493 | Boyle et al. | Jul 2012 | B2 |
| 8226711 | Mortier et al. | Jul 2012 | B2 |
| 8241304 | Bachman | Aug 2012 | B2 |
| 8241351 | Cabiri | Aug 2012 | B2 |
| 8252050 | Maisano | Aug 2012 | B2 |
| 8252051 | Chau et al. | Aug 2012 | B2 |
| 8262725 | Subramanian | Sep 2012 | B2 |
| 8277502 | Miller et al. | Oct 2012 | B2 |
| 8287591 | Keidar et al. | Oct 2012 | B2 |
| 8292884 | Levine et al. | Oct 2012 | B2 |
| 8308796 | Lashinski et al. | Nov 2012 | B2 |
| 8323336 | Hill et al. | Dec 2012 | B2 |
| 8337390 | Ferrazzi | Dec 2012 | B2 |
| 8353956 | Miller et al. | Jan 2013 | B2 |
| 8361086 | Allen et al. | Jan 2013 | B2 |
| 8377118 | Lashinski et al. | Feb 2013 | B2 |
| 8382796 | Blaeser et al. | Feb 2013 | B2 |
| 8382828 | Roberts | Feb 2013 | B2 |
| 8382829 | Call et al. | Feb 2013 | B1 |
| RE44075 | Williamson, IV et al. | Mar 2013 | E |
| 8398708 | Meiri et al. | Mar 2013 | B2 |
| 8408214 | Spenser | Apr 2013 | B2 |
| 8413573 | Rebecchi | Apr 2013 | B2 |
| 8414644 | Quadri et al. | Apr 2013 | B2 |
| 8449606 | Eliasen et al. | May 2013 | B2 |
| 8454683 | Rafiee et al. | Jun 2013 | B2 |
| 8470028 | Thornton | Jun 2013 | B2 |
| 8500800 | Maisano et al. | Aug 2013 | B2 |
| 8506624 | Vidlund et al. | Aug 2013 | B2 |
| 8523881 | Cabiri et al. | Sep 2013 | B2 |
| 8545553 | Zipory et al. | Oct 2013 | B2 |
| 8608797 | Gross et al. | Dec 2013 | B2 |
| 8657872 | Seguin | Feb 2014 | B2 |
| 8690939 | Miller et al. | Apr 2014 | B2 |
| 8715342 | Zipory et al. | May 2014 | B2 |
| 8734467 | Miller et al. | May 2014 | B2 |
| 8784483 | Navia | Jul 2014 | B2 |
| 8790394 | Miller et al. | Jul 2014 | B2 |
| 8795352 | O'Beirne et al. | Aug 2014 | B2 |
| 8808368 | Maisano et al. | Aug 2014 | B2 |
| 8845717 | Khairkhahan et al. | Sep 2014 | B2 |
| 8858623 | Miller et al. | Oct 2014 | B2 |
| 8888843 | Khairkhahan et al. | Nov 2014 | B2 |
| 8888844 | Eliasen et al. | Nov 2014 | B2 |
| 8911494 | Hammer et al. | Dec 2014 | B2 |
| 8926695 | Gross et al. | Jan 2015 | B2 |
| 8926696 | Cabiri et al. | Jan 2015 | B2 |
| 8926697 | Gross et al. | Jan 2015 | B2 |
| 8940042 | Miller et al. | Jan 2015 | B2 |
| 8940044 | Hammer et al. | Jan 2015 | B2 |
| 9005279 | Gabbay | Apr 2015 | B2 |
| 9011520 | Miller et al. | Apr 2015 | B2 |
| 9011530 | Reich et al. | Apr 2015 | B2 |
| 9056006 | Edelman et al. | Jun 2015 | B2 |
| 9119719 | Zipory et al. | Sep 2015 | B2 |
| 9180007 | Reich et al. | Nov 2015 | B2 |
| 9192472 | Gross et al. | Nov 2015 | B2 |
| 9204964 | Dahlgren et al. | Dec 2015 | B2 |
| 9232999 | Maurer et al. | Jan 2016 | B2 |
| 9265608 | Miller et al. | Feb 2016 | B2 |
| 9277994 | Miller et al. | Mar 2016 | B2 |
| 9351830 | Gross et al. | May 2016 | B2 |
| 9414921 | Miller et al. | Aug 2016 | B2 |
| 9452048 | O'beirne et al. | Sep 2016 | B2 |
| 9474606 | Zipory et al. | Oct 2016 | B2 |
| 9526613 | Gross et al. | Dec 2016 | B2 |
| 9549817 | Rafiee | Jan 2017 | B2 |
| 9554906 | Aklog et al. | Jan 2017 | B2 |
| 9561104 | Miller et al. | Feb 2017 | B2 |
| 9592118 | Khairkhahan et al. | Mar 2017 | B2 |
| 9592121 | Khairkhahan | Mar 2017 | B1 |
| 9592122 | Zipory et al. | Mar 2017 | B2 |
| 9610162 | Zipory et al. | Apr 2017 | B2 |
| 9610163 | Khairkhahan et al. | Apr 2017 | B2 |
| 9622861 | Miller et al. | Apr 2017 | B2 |
| 9636224 | Zipory et al. | May 2017 | B2 |
| 9662209 | Gross et al. | May 2017 | B2 |
| 9713530 | Cabiri et al. | Jul 2017 | B2 |
| 9724192 | Sheps et al. | Aug 2017 | B2 |
| 9730793 | Reich et al. | Aug 2017 | B2 |
| 9775709 | Miller et al. | Oct 2017 | B2 |
| 9814572 | Edelman et al. | Nov 2017 | B2 |
| 9872769 | Gross et al. | Jan 2018 | B2 |
| 9883943 | Gross et al. | Feb 2018 | B2 |
| 9918840 | Reich et al. | Mar 2018 | B2 |
| 9937042 | Cabiri et al. | Apr 2018 | B2 |
| 9949828 | Sheps et al. | Apr 2018 | B2 |
| 9968452 | Sheps et al. | May 2018 | B2 |
| 9968454 | Reich et al. | May 2018 | B2 |
| 9974653 | Gross et al. | May 2018 | B2 |
| 10028832 | Quill et al. | Jul 2018 | B2 |
| 10098737 | Miller et al. | Oct 2018 | B2 |
| 10123874 | Khairkhahan et al. | Nov 2018 | B2 |
| 10130472 | O'beirne et al. | Nov 2018 | B2 |
| 10166098 | Khairkhahan et al. | Jan 2019 | B2 |
| 10195030 | Gross et al. | Feb 2019 | B2 |
| 10226342 | Kutzik et al. | Mar 2019 | B2 |
| 10251635 | Khairkhahan et al. | Apr 2019 | B2 |
| 10265170 | Zipory et al. | Apr 2019 | B2 |
| 10299793 | Zipory et al. | May 2019 | B2 |
| 10350068 | Miller et al. | Jul 2019 | B2 |
| 10357366 | Gross et al. | Jul 2019 | B2 |
| 10363136 | Miller et al. | Jul 2019 | B2 |
| 10363137 | Gross et al. | Jul 2019 | B2 |
| 10368982 | Weber et al. | Aug 2019 | B2 |
| 10376266 | Herman et al. | Aug 2019 | B2 |
| 10376365 | Khairkhahan et al. | Aug 2019 | B2 |
| 10383726 | Kramer | Aug 2019 | B2 |
| 10433955 | Edelman et al. | Oct 2019 | B2 |
| 10449046 | Rafiee | Oct 2019 | B2 |
| 10449333 | Hammer et al. | Oct 2019 | B2 |
| 10470882 | Gross et al. | Nov 2019 | B2 |
| 10470883 | Khairkhahan et al. | Nov 2019 | B2 |
| 10478303 | Khairkhahan et al. | Nov 2019 | B2 |
| 10492909 | Miller et al. | Dec 2019 | B2 |
| 10500048 | Khairkhahan et al. | Dec 2019 | B2 |
| 10512542 | Khairkhahan et al. | Dec 2019 | B2 |
| 10517719 | Miller et al. | Dec 2019 | B2 |
| 10543088 | Lashinski | Jan 2020 | B2 |
| 10548729 | Zipory et al. | Feb 2020 | B2 |
| 10548731 | Lashinski et al. | Feb 2020 | B2 |
| 10561498 | Gross et al. | Feb 2020 | B2 |
| 10568738 | Sheps et al. | Feb 2020 | B2 |
| 10610360 | Reich et al. | Apr 2020 | B2 |
| 10653524 | Khairkhahan et al. | May 2020 | B2 |
| 10702386 | Khairkhahan et al. | Jul 2020 | B2 |
| 10751180 | Schewel | Aug 2020 | B2 |
| 11000372 | Khairkhahan et al. | May 2021 | B2 |
| 11160656 | Khairkhahan | Nov 2021 | B2 |
| 20010007956 | Letac et al. | Jul 2001 | A1 |
| 20010021872 | Bailey et al. | Sep 2001 | A1 |
| 20020029080 | Mortier et al. | Mar 2002 | A1 |
| 20020058995 | Stevens | May 2002 | A1 |
| 20020116024 | Goldberg et al. | Aug 2002 | A1 |
| 20020138135 | Duerig | Sep 2002 | A1 |
| 20020188301 | Dallara et al. | Dec 2002 | A1 |
| 20030023248 | Parodi | Jan 2003 | A1 |
| 20030100943 | Bolduc | May 2003 | A1 |
| 20030105474 | Bonutti | Jun 2003 | A1 |
| 20030135263 | Rourke et al. | Jul 2003 | A1 |
| 20030191497 | Cope | Oct 2003 | A1 |
| 20030199975 | Gabbay | Oct 2003 | A1 |
| 20040082956 | Baldwin et al. | Apr 2004 | A1 |
| 20040088047 | Spence et al. | May 2004 | A1 |
| 20040143323 | Chawla | Jul 2004 | A1 |
| 20040172046 | Hlavka et al. | Sep 2004 | A1 |
| 20040193217 | Lubbers et al. | Sep 2004 | A1 |
| 20040210307 | Khairkhahan | Oct 2004 | A1 |
| 20050004665 | Aklog | Jan 2005 | A1 |
| 20050004668 | Aklog et al. | Jan 2005 | A1 |
| 20050010287 | Macoviak et al. | Jan 2005 | A1 |
| 20050075727 | Wheatley et al. | Apr 2005 | A1 |
| 20050096740 | Langberg et al. | May 2005 | A1 |
| 20050107871 | Realyvasquez | May 2005 | A1 |
| 20050159810 | Filsoufi | Jul 2005 | A1 |
| 20050177180 | Kaganov et al. | Aug 2005 | A1 |
| 20050228495 | Macoviak | Oct 2005 | A1 |
| 20050261708 | Pasricha et al. | Nov 2005 | A1 |
| 20050283232 | Gabbay | Dec 2005 | A1 |
| 20060058871 | Zakay et al. | Mar 2006 | A1 |
| 20060122608 | Fallin et al. | Jun 2006 | A1 |
| 20060149368 | Spence | Jul 2006 | A1 |
| 20060190030 | To et al. | Aug 2006 | A1 |
| 20060252984 | Rahdert et al. | Nov 2006 | A1 |
| 20070005069 | Contiliano et al. | Jan 2007 | A1 |
| 20070049970 | Belef et al. | Mar 2007 | A1 |
| 20070093890 | Eliasen | Apr 2007 | A1 |
| 20070112352 | Sorensen et al. | May 2007 | A1 |
| 20070112425 | Schaller et al. | May 2007 | A1 |
| 20070118151 | Davidson | May 2007 | A1 |
| 20070129758 | Saadat | Jun 2007 | A1 |
| 20070185571 | Kapadia et al. | Aug 2007 | A1 |
| 20070233239 | Navia et al. | Oct 2007 | A1 |
| 20070239272 | Navia et al. | Oct 2007 | A1 |
| 20070244554 | Rafiee et al. | Oct 2007 | A1 |
| 20070244555 | Rafiee et al. | Oct 2007 | A1 |
| 20070244556 | Rafiee et al. | Oct 2007 | A1 |
| 20070250160 | Rafiee | Oct 2007 | A1 |
| 20070255399 | Eliasen et al. | Nov 2007 | A1 |
| 20070265658 | Nelson et al. | Nov 2007 | A1 |
| 20070265700 | Eliasen et al. | Nov 2007 | A1 |
| 20070265702 | Lattouf | Nov 2007 | A1 |
| 20070293943 | Quinn | Dec 2007 | A1 |
| 20080065204 | Macoviak et al. | Mar 2008 | A1 |
| 20080109075 | Keranen | May 2008 | A1 |
| 20080125860 | Webler et al. | May 2008 | A1 |
| 20080125861 | Webler | May 2008 | A1 |
| 20080195205 | Schwartz | Aug 2008 | A1 |
| 20080262609 | Gross et al. | Oct 2008 | A1 |
| 20080319541 | Filsoufi | Dec 2008 | A1 |
| 20090012354 | Wood | Jan 2009 | A1 |
| 20090088836 | Bishop et al. | Apr 2009 | A1 |
| 20090177277 | Milo | Jul 2009 | A1 |
| 20090234404 | Fitzgerald et al. | Sep 2009 | A1 |
| 20090259304 | O'Beirne et al. | Oct 2009 | A1 |
| 20090259307 | Gross et al. | Oct 2009 | A1 |
| 20090287304 | Dahlgren et al. | Nov 2009 | A1 |
| 20090326648 | Machold et al. | Dec 2009 | A1 |
| 20100069954 | Blaeser et al. | Mar 2010 | A1 |
| 20100121435 | Subramanian et al. | May 2010 | A1 |
| 20100131057 | Subramanian et al. | May 2010 | A1 |
| 20100161043 | Maisano et al. | Jun 2010 | A1 |
| 20100161047 | Cabiri et al. | Jun 2010 | A1 |
| 20100249947 | Lesh et al. | Sep 2010 | A1 |
| 20100262233 | He | Oct 2010 | A1 |
| 20100280603 | Maisano et al. | Nov 2010 | A1 |
| 20100280604 | Zipory et al. | Nov 2010 | A1 |
| 20100280605 | Hammer | Nov 2010 | A1 |
| 20100280606 | Naor | Nov 2010 | A1 |
| 20100286767 | Zipory et al. | Nov 2010 | A1 |
| 20100298929 | Thornton et al. | Nov 2010 | A1 |
| 20100312333 | Navia et al. | Dec 2010 | A1 |
| 20110004299 | Navia et al. | Jan 2011 | A1 |
| 20110082538 | Dahlgren et al. | Apr 2011 | A1 |
| 20110106245 | Miller et al. | May 2011 | A1 |
| 20110106247 | Miller et al. | May 2011 | A1 |
| 20110137397 | Chau et al. | Jun 2011 | A1 |
| 20110166649 | Gross et al. | Jul 2011 | A1 |
| 20110224785 | Hacohen | Sep 2011 | A1 |
| 20110288635 | Miller et al. | Nov 2011 | A1 |
| 20110301698 | Miller et al. | Dec 2011 | A1 |
| 20120016468 | Robin et al. | Jan 2012 | A1 |
| 20120022557 | Cabiri et al. | Jan 2012 | A1 |
| 20120022644 | Reich et al. | Jan 2012 | A1 |
| 20120078360 | Rafiee | Mar 2012 | A1 |
| 20120136436 | Cabiri et al. | May 2012 | A1 |
| 20120165930 | Gifford et al. | Jun 2012 | A1 |
| 20120197388 | Khairkhahan et al. | Aug 2012 | A1 |
| 20120203336 | Annest | Aug 2012 | A1 |
| 20120283757 | Miller et al. | Nov 2012 | A1 |
| 20120323316 | Chau et al. | Dec 2012 | A1 |
| 20120330410 | Hammer et al. | Dec 2012 | A1 |
| 20120330411 | Gross et al. | Dec 2012 | A1 |
| 20130023985 | Khairkhahan et al. | Jan 2013 | A1 |
| 20130096672 | Reich et al. | Apr 2013 | A1 |
| 20130116776 | Gross et al. | May 2013 | A1 |
| 20130116780 | Miller et al. | May 2013 | A1 |
| 20130131792 | Miller et al. | May 2013 | A1 |
| 20130190861 | Chau et al. | Jul 2013 | A1 |
| 20130190866 | Zipory et al. | Jul 2013 | A1 |
| 20130238024 | Taylor et al. | Sep 2013 | A1 |
| 20130282028 | Conklin et al. | Oct 2013 | A1 |
| 20130338763 | Rowe et al. | Dec 2013 | A1 |
| 20140018906 | Rafiee | Jan 2014 | A1 |
| 20140025163 | Padala et al. | Jan 2014 | A1 |
| 20140039615 | Padala et al. | Feb 2014 | A1 |
| 20140067048 | Chau | Mar 2014 | A1 |
| 20140094903 | Miller et al. | Apr 2014 | A1 |
| 20140128965 | Rafiee | May 2014 | A1 |
| 20140142695 | Gross et al. | May 2014 | A1 |
| 20140148898 | Gross et al. | May 2014 | A1 |
| 20140222137 | Miller et al. | Aug 2014 | A1 |
| 20140243963 | Sheps et al. | Aug 2014 | A1 |
| 20140276648 | Hammer et al. | Sep 2014 | A1 |
| 20140277088 | Friedman | Sep 2014 | A1 |
| 20140309661 | Sheps et al. | Oct 2014 | A1 |
| 20140343668 | Zipory et al. | Nov 2014 | A1 |
| 20140358223 | Rafiee et al. | Dec 2014 | A1 |
| 20140379075 | Maurer et al. | Dec 2014 | A1 |
| 20150012087 | Miller et al. | Jan 2015 | A1 |
| 20150039083 | Rafiee et al. | Feb 2015 | A1 |
| 20150081014 | Gross et al. | Mar 2015 | A1 |
| 20150100116 | Mohl et al. | Apr 2015 | A1 |
| 20150105855 | Cabiri et al. | Apr 2015 | A1 |
| 20150112429 | Khairkhahan et al. | Apr 2015 | A1 |
| 20150112432 | Reich et al. | Apr 2015 | A1 |
| 20150119981 | Khairkhahan et al. | Apr 2015 | A1 |
| 20150164637 | Khairkhahan et al. | Jun 2015 | A1 |
| 20150182336 | Zipory et al. | Jul 2015 | A1 |
| 20150202043 | Zakai et al. | Jul 2015 | A1 |
| 20150230924 | Miller et al. | Aug 2015 | A1 |
| 20150257877 | Hernandez | Sep 2015 | A1 |
| 20150272586 | Herman et al. | Oct 2015 | A1 |
| 20150272734 | Sheps et al. | Oct 2015 | A1 |
| 20150297212 | Reich et al. | Oct 2015 | A1 |
| 20150366556 | Khairkhahan et al. | Dec 2015 | A1 |
| 20150366666 | Khairkhahan et al. | Dec 2015 | A1 |
| 20160008132 | Cabiri et al. | Jan 2016 | A1 |
| 20160030176 | Mohl et al. | Feb 2016 | A1 |
| 20160058557 | Reich et al. | Mar 2016 | A1 |
| 20160074164 | Naor | Mar 2016 | A1 |
| 20160089233 | Lee et al. | Mar 2016 | A1 |
| 20160106437 | van der Burg et al. | Apr 2016 | A1 |
| 20160113767 | Miller et al. | Apr 2016 | A1 |
| 20160157862 | Hernandez et al. | Jun 2016 | A1 |
| 20160158008 | Miller et al. | Jun 2016 | A1 |
| 20160262755 | Zipory et al. | Sep 2016 | A1 |
| 20160324639 | Nguyen et al. | Nov 2016 | A1 |
| 20160331523 | Chau et al. | Nov 2016 | A1 |
| 20160361168 | Gross et al. | Dec 2016 | A1 |
| 20160361169 | Gross et al. | Dec 2016 | A1 |
| 20170000609 | Gross et al. | Jan 2017 | A1 |
| 20170100249 | Miller et al. | Apr 2017 | A1 |
| 20170105839 | Subramanian et al. | Apr 2017 | A1 |
| 20170135815 | Gross et al. | May 2017 | A1 |
| 20170135816 | Lashinski et al. | May 2017 | A1 |
| 20170189186 | Mohl | Jul 2017 | A1 |
| 20170196691 | Zipory et al. | Jul 2017 | A1 |
| 20170209270 | Miller et al. | Jul 2017 | A1 |
| 20170245993 | Gross et al. | Aug 2017 | A1 |
| 20170245994 | Khairkhahan et al. | Aug 2017 | A1 |
| 20170258588 | Zipory et al. | Sep 2017 | A1 |
| 20170258590 | Khairkhahan et al. | Sep 2017 | A1 |
| 20170265995 | Khairkhahan et al. | Sep 2017 | A1 |
| 20170296340 | Gross et al. | Oct 2017 | A1 |
| 20170325958 | Reich et al. | Nov 2017 | A1 |
| 20170325959 | Sheps et al. | Nov 2017 | A1 |
| 20170354500 | Martinez et al. | Dec 2017 | A1 |
| 20170367825 | Cabiri et al. | Dec 2017 | A1 |
| 20180008409 | Kutzik et al. | Jan 2018 | A1 |
| 20180014933 | Miller et al. | Jan 2018 | A1 |
| 20180014934 | Miller et al. | Jan 2018 | A1 |
| 20180049875 | Iflah et al. | Feb 2018 | A1 |
| 20180116797 | Miller et al. | May 2018 | A9 |
| 20180125657 | Dahlgren et al. | May 2018 | A1 |
| 20180228608 | Sheps et al. | Aug 2018 | A1 |
| 20180250133 | Reich et al. | Sep 2018 | A1 |
| 20180256318 | Khairkhahan | Sep 2018 | A1 |
| 20180256333 | Cabiri et al. | Sep 2018 | A1 |
| 20180256334 | Sheps et al. | Sep 2018 | A1 |
| 20180263776 | Gross et al. | Sep 2018 | A1 |
| 20180263777 | Gross et al. | Sep 2018 | A1 |
| 20180318080 | Quill et al. | Nov 2018 | A1 |
| 20190008641 | Dahlgren et al. | Jan 2019 | A1 |
| 20190046318 | Miller et al. | Feb 2019 | A1 |
| 20190070004 | Ifah et al. | Mar 2019 | A1 |
| 20190076247 | Zeng | Mar 2019 | A1 |
| 20190076249 | Khairkhahan | Mar 2019 | A1 |
| 20190125325 | Sheps et al. | May 2019 | A1 |
| 20190133586 | Zipory et al. | May 2019 | A1 |
| 20190151090 | Gross et al. | May 2019 | A1 |
| 20190151093 | Keidar et al. | May 2019 | A1 |
| 20190159898 | Kutzik et al. | May 2019 | A1 |
| 20190167425 | Reich et al. | Jun 2019 | A1 |
| 20190175344 | Khairkhahan | Jun 2019 | A1 |
| 20190201191 | McLean et al. | Jul 2019 | A1 |
| 20190216600 | Zipory et al. | Jul 2019 | A1 |
| 20190254821 | Rafiee et al. | Aug 2019 | A1 |
| 20190269512 | Lashinski | Sep 2019 | A9 |
| 20190269513 | Cabiri et al. | Sep 2019 | A9 |
| 20190274830 | Miller et al. | Sep 2019 | A1 |
| 20190282358 | Khairkhahan et al. | Sep 2019 | A1 |
| 20190282364 | Khairkhahan et al. | Sep 2019 | A1 |
| 20190298332 | Khairkhahan et al. | Oct 2019 | A1 |
| 20190321049 | Herman et al. | Oct 2019 | A1 |
| 20190336288 | Gross et al. | Nov 2019 | A1 |
| 20190336289 | Miller et al. | Nov 2019 | A1 |
| 20190350703 | Weber et al. | Nov 2019 | A1 |
| 20190350705 | Schewel et al. | Nov 2019 | A1 |
| 20190374343 | Lashinski et al. | Dec 2019 | A1 |
| 20190374750 | Hammer et al. | Dec 2019 | A1 |
| 20190380834 | Rafiee | Dec 2019 | A1 |
| 20200015971 | Brauon et al. | Jan 2020 | A1 |
| 20200030097 | Khairkhahan et al. | Jan 2020 | A1 |
| 20200038186 | Gross et al. | Feb 2020 | A1 |
| 20200100899 | Miller et al. | Apr 2020 | A1 |
| 20200113685 | Miller et al. | Apr 2020 | A1 |
| 20200205966 | Khairkhahan et al. | Jul 2020 | A1 |
| 20200205975 | Khairkhahan | Jul 2020 | A1 |
| 20200205980 | Khairkhahan et al. | Jul 2020 | A1 |
| 20200214841 | Khairkhahan et al. | Jul 2020 | A1 |
| 20200222185 | Kappetein et al. | Jul 2020 | A1 |
| 20200275974 | Gifford et al. | Sep 2020 | A1 |
| 20200289265 | Gifford et al. | Sep 2020 | A1 |
| 20200330229 | Serraf et al. | Oct 2020 | A1 |
| 20200337843 | Khairkhahan et al. | Oct 2020 | A1 |
| 20200383776 | Schewel | Dec 2020 | A1 |
| 20200397567 | Khairkhahan et al. | Dec 2020 | A1 |
| 20210085462 | Gifford et al. | Mar 2021 | A1 |
| 20210196462 | Khairkhahan | Jul 2021 | A1 |
| 20210298901 | Khairkhahan et al. | Sep 2021 | A1 |
| 20220000621 | Gifford et al. | Jan 2022 | A1 |
| 20220039944 | Khairkhahan | Feb 2022 | A1 |
| 20220039951 | Khairkhahan | Feb 2022 | A1 |
| 20220054269 | Khairkhahan | Feb 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 102256568 | Dec 2002 | CN |
| 1984621 | Jun 2007 | CN |
| 101056596 | Oct 2007 | CN |
| 101068508 | Nov 2007 | CN |
| 101947146 | Jan 2011 | CN |
| 102065777 | May 2011 | CN |
| 102458309 | May 2012 | CN |
| 202821715 | Mar 2013 | CN |
| 103338726 | Oct 2013 | CN |
| 102905648 | Jan 2015 | CN |
| 104394803 | Mar 2015 | CN |
| 104582637 | Apr 2015 | CN |
| 105451688 | Mar 2016 | CN |
| 1 294 310 | Mar 2003 | EP |
| 1 959 865 | Aug 2008 | EP |
| 2 410 948 | Feb 2012 | EP |
| 1 796 597 | Jan 2013 | EP |
| 2 661 239 | Nov 2013 | EP |
| 2 667 824 | Dec 2013 | EP |
| 2 995 279 | Mar 2016 | EP |
| S54-088693 | Jul 1979 | JP |
| 2005-535384 | Nov 2005 | JP |
| 2007-518492 | Jul 2007 | JP |
| 2008-517672 | May 2008 | JP |
| 2010-511469 | Apr 2010 | JP |
| 2012-511402 | May 2012 | JP |
| 2012-520716 | Sep 2012 | JP |
| 2014-510563 | May 2014 | JP |
| 2014-231015 | Dec 2014 | JP |
| 2015-523898 | Aug 2016 | JP |
| 2016-533798 | Nov 2016 | JP |
| 2017-18675 | Jan 2017 | JP |
| WO 97007744 | Mar 1997 | WO |
| WO 9953869 | Oct 1998 | WO |
| WO 2004014258 | Feb 2004 | WO |
| WO 2005069875 | Aug 2005 | WO |
| WO 2006032051 | Mar 2006 | WO |
| WO 2006041877 | Apr 2006 | WO |
| WO 2006086434 | Aug 2006 | WO |
| WO 2007062054 | May 2007 | WO |
| WO 2007135101 | Nov 2007 | WO |
| WO 2007140470 | Dec 2007 | WO |
| WO 2008068756 | Jun 2008 | WO |
| WO 2008141322 | Nov 2008 | WO |
| WO 2010106438 | Sep 2010 | WO |
| WO 2011037891 | Mar 2011 | WO |
| WO 2011047168 | Apr 2011 | WO |
| WO 2012061809 | May 2012 | WO |
| WO 2012092437 | Jul 2012 | WO |
| WO 2012102928 | Aug 2012 | WO |
| WO 2013131069 | Sep 2013 | WO |
| WO 2013173587 | Nov 2013 | WO |
| WO 2013178335 | Dec 2013 | WO |
| WO 2013192107 | Dec 2013 | WO |
| WO 2014181336 | Nov 2014 | WO |
| WO 2014207575 | Dec 2014 | WO |
| WO 2015020971 | Feb 2015 | WO |
| WO 2015052570 | Apr 2015 | WO |
| WO 2015061533 | Apr 2015 | WO |
| WO 2015195823 | Dec 2015 | WO |
| WO 2015200497 | Dec 2015 | WO |
| WO 2016178136 | Nov 2016 | WO |
| WO 2016183485 | Nov 2016 | WO |
| WO 2017079279 | May 2017 | WO |
| WO 2017136596 | Aug 2017 | WO |
| WO 2019116322 | Jun 2019 | WO |
| WO 2019222694 | Nov 2019 | WO |
| WO 2019241777 | Dec 2019 | WO |
| Entry |
|---|
| Biocina et al., Mitral Valve Repair With The New Mitrofast® Repair System, Dubrava University Hospital, Zagreb, Crotia, Mitrofast Abstract European Soc CVS 55th Congress—May 11-14, 2006 Suppl 1 to vol. 5. |
| Biocina, The arteficial coaptation surface concept in mitral valve repair, University of Zagreb School of Medicine, Department of Cardiac Surgery, Savudrija Mitrofast 2010. |
| Chiam et al., Percutaneous Transcatheter Mitral Valve Repair, The American College of Cardiology Foundation, JACC: Cardiovascular Interventions, vol. 4 No. 1, Jan. 2011:1-13. |
| Jassar et al., Posterior Leaflet Augmentation in Ischemic Mitral Regurgitation Increases Leaflet Coaptation and Mobility, The Society of Thoracic Surgeons, Ann Thorac Surg 2012; 94:1438-45. |
| Langer et al., Posterior mitral leaflet extension: An adjunctive repair option for ischemic mitral regurgitation?, Surgery for Acquired Cardiovascular Disease, The Journal of Thoracic and Cardiovascular Surgery, Apr. 2006, downloaded Jun. 18, 2011. |
| Mohl et al., The Angel Valve Concept, Vienna University of Technology, Medical University of Vienna, Technology Offer, 1 page. |
| Mohl et al., An Innovative Concept For Transcatheter Treatment of Annular Dilatation and Restrictive Leaflet Motion in Mitral Insufficiency, Medical University of Vienna, 1 page. |
| Piemonte et al., Cardiovascular™: The Mitral Valve Spacer, Presented at Transcatheter Cardiovascular Therapeutics Conference—TCT Conference, Oct. 2008. |
| Rumel et al., The Correction of Mitral Insufficiency with a Trans-Valvular Polyvinyl Formalinized Plastic (Ivalon) Sponge Prosthesis: A Preliminary Report, American College of Chest Physicians, 1958;33;401-413, Dec. 2, 2010. |
| International Preliminary Report on Patentability for PCT/US2012/021744 dated Aug. 8, 2013 in 15 pages. |
| International Search Report for Application No. PCT/US2013/046173 dated Oct. 4, 2013 in 15 pages. |
| International Search Report for Application No. PCT/US2014/061901 dated Jan. 26, 2015 in 14 pages. |
| International Search Report for Application No. PCT/US2015/036260 dated Oct. 1, 2015 in 20 pages. |
| International Search Report for Application No. PCT/US2015/037451 dated Oct. 6, 2015 in 12 pages. |
| International Search Report for Application No. PCT/US2016/060094 dated Feb. 9, 2017 in 8 pages. |
| International Search Report for Application No. PCT/US2018/022043 dated Jun. 25, 2018 in 13 pages. |
| Extended European Search Report, EP 12738989.8, dated May 24, 2016. |
| Office Action for EP 12738989.8 dated Mar. 3, 2017. |
| Office Action for EP 12738989.8 dated Sep. 19, 2017. |
| Extended European Search Report, EP 13806272.4, dated Nov. 11, 2015. |
| Extended European Search Report, EP 14856738.1, dated Jun. 7, 2017. |
| Extended European Search Report, EP 15809346.8, dated Feb. 13, 2018. |
| Extended European Search Report, EP 15812032.9, dated Oct. 18, 2017. |
| Extended European Search Report, EP 16862864.2, dated May 10, 2019. |
| Office Action for CA 2,825,520 dated Nov. 27, 2017. |
| Office Action for CA 2,825,520 dated Aug. 21, 2018. |
| Office Action for CA 2,877,344 dated Mar. 12, 2019. |
| Office Action for CA 2,877,344 dated Oct. 9, 2019. |
| Office Action for CA 2,877,344 dated Jul. 21, 2020. |
| Office Action for CN 201280006673.7 dated Dec. 10, 2014. |
| Office Action for CN 201280006673.7 dated Sep. 22, 2015. |
| Office Action for CN 201280006673.7 dated Feb. 1, 2016. |
| Office Action for CN 201380044122.4 dated Nov. 4, 2015. |
| Office Action for CN 201380044122.4 dated Aug. 24, 2016. |
| Office Action for CN 201480070933.6 dated May 10, 2017. |
| Office Action for CN 201480070933.6 dated Dec. 25, 2017. |
| Office Action for CN 201480070933.6 dated Aug. 10, 2018. |
| Office Action forCN 201480070933.6 dated Apr. 17, 2019. |
| Office Action for CN 201580044329.0 dated Jan. 17, 2018. |
| Office Action for CN 201580044329.0 dated Jul. 29, 2019. |
| Office Action for CN 201580045375.2 dated Mar. 29, 2018. |
| Office Action for CN 201580045375.2 dated Nov. 12, 2018. |
| Office Action for CN 201680077877.8 dated Aug. 15, 2019. |
| Office Action for EP 15812032.9, dated Oct. 10, 2019. |
| Office Action for JP 2013-552015 dated Dec. 7, 2015. |
| Office Action for JP 2013-552015 dated Oct. 7, 2016. |
| Office Action for JP 2013-552015 dated Jun. 5, 2017. |
| Office Action for JP 2015-518499 dated Feb. 27, 2017. |
| Office Action for JP 2015-518499 dated Aug. 31, 2017. |
| Office Action for JP 2015-518499 dated Aug. 20, 2018. |
| Office Action for JP 2016-525999 dated Jul. 9, 2018. |
| Office Action for JP 2016-525999 dated Jun. 27, 2019. |
| Office Action for JP 2016-525999 dated Mar. 16, 2020. |
| Office Action for 2016-573983 dated Apr. 1, 2019. |
| Office Action for 2016-573983 dated Nov. 11, 2019. |
| Office Action for JP 2016-574967 dated May 7, 2019. |
| Office Action for JP 2016-574967 dated Dec. 26, 2019. |
| International Search Report for Application No. PCT/US2019/050331 dated Jan. 23, 2020 in 9 pages. |
| Office Action for CN 201580044329.0 dated Mar. 3, 2020. |
| Office Action for 2016-573983 dated May 11, 2020. |
| Office Action for CN 201580044329.0 dated Aug. 26, 2020. |
| Office Action for EP 15812032.9, dated Jul. 6, 2020. |
| Office Action for JP 2016-574967 dated Jun. 29, 2020. |
| Office Action for JP 2018-543021 dated Oct. 27, 2020. |
| Office Action for CA 2,877,344 dated Dec. 23, 2020. |
| Office Action for CA 2,934,182 dated Dec. 9, 2020. |
| Office Action for JP 2020-082001 dated Mar. 29, 2021. |
| Extended European Search Report, EP 18768736.3, dated Oct. 9, 2020. |
| International Search Report for Application No. PCT/US2020/065261 dated Apr. 13, 2021 in 13 pages. |
| Office Action for CN 201880031519.2 dated May 19, 2021. |
| Office Action for EP 13806272.4, dated Mar. 23, 2021. |
| Office Action for EP 14856738.1, dated Apr. 23, 2021. |
| Office Action for JP 2020-085273 dated May 31, 2021. |
| Office Action for CA 2,934,182 dated Jun. 30, 2021. |
| Office Action for CA 2,958,065 dated Jul. 9, 2021. |
| Office Action for JP 2018-543021 dated Oct. 4, 2021. |
| Office Action for JP 2020-085273 dated Aug. 23, 2021. |
| Office Action for JP 2020-082001 dated Nov. 29, 2021. |
| Office Action for CA 2,934,182 dated Mar. 2, 2022. |
| Office Action for CA 2,958,065 dated Mar. 2, 2022. |
| Office Action for 2020-041944 dated Feb. 21, 2022. |
| Office Action for 2019-572351 dated Feb. 28, 2022. |
| Number | Date | Country | |
|---|---|---|---|
| 20220039944 A1 | Feb 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61437397 | Jan 2011 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16675565 | Nov 2019 | US |
| Child | 17480684 | US | |
| Parent | 15475629 | Mar 2017 | US |
| Child | 16675565 | US | |
| Parent | 14500470 | Sep 2014 | US |
| Child | 15475629 | US | |
| Parent | 13099532 | May 2011 | US |
| Child | 14500470 | US |
